US20200093874A1 - Compositions and methods for the treatment of netherton syndrome - Google Patents

Compositions and methods for the treatment of netherton syndrome Download PDF

Info

Publication number
US20200093874A1
US20200093874A1 US16/581,150 US201916581150A US2020093874A1 US 20200093874 A1 US20200093874 A1 US 20200093874A1 US 201916581150 A US201916581150 A US 201916581150A US 2020093874 A1 US2020093874 A1 US 2020093874A1
Authority
US
United States
Prior art keywords
recombinant
polypeptide
genome
spink5
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/581,150
Other languages
English (en)
Inventor
Pooja Agarwal
Suma Krishnan
John C. FREEDMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Krystal Biotech Inc
Original Assignee
Krystal Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krystal Biotech Inc filed Critical Krystal Biotech Inc
Priority to US16/581,150 priority Critical patent/US20200093874A1/en
Publication of US20200093874A1 publication Critical patent/US20200093874A1/en
Assigned to Krystal Biotech, Inc. reassignment Krystal Biotech, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FREEDMAN, John C., AGARWAL, POOJA, KRISHNAN, SUMA
Priority to US17/871,805 priority patent/US11642384B2/en
Priority to US18/187,884 priority patent/US20230218691A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase

Definitions

  • the present disclosure relates, in part, to recombinant nucleic acids comprising one or more polynucleotides encoding a Serine Protease Inhibitor Kazal-type (SPINK) polypeptide (e.g., a human SPINK5 polypeptide), viruses comprising the same, pharmaceutical compositions, formulations, and medicaments thereof, and methods of their use (e.g., for the treatment of Netherton Syndrome).
  • SPINK Serine Protease Inhibitor Kazal-type
  • Netherton Syndrome also referred to as Comél-Netherton Syndrome
  • NS is a debilitating autosomal recessive skin disorder that causes defective keratinization, severe skin barrier defects, and recurrent infections.
  • Patients present shortly after birth with generalized rashes that develop into severe ichthyosis (Comèl, 1949 . Dermatologica. 98(3):133-6).
  • Infants with more severe NS symptoms are associated with failure to thrive, hypernatremic dehydration secondary to excess fluid loss, delayed growth, short stature, and recurrent infections (Jones et al., 1986 . Br J Dermatol. 114(6):741-3; Hausser et al., 1996 . Pediatr Dermatol. 13(3):183-99).
  • Postnatal mortality rates for Netherton Syndrome are extremely high, with up to 20% of patients failing to reach their first birthday (Renner et al., 2009 . J Allergy Clin Immunol. 124(3):536-43)
  • Netherton Syndrome is characterized by congenital ichthyosiform erythroderma, hair shaft defects, recurrent infections, and a defective skin barrier (Judge et al., 1994 . Br J Dermatol. 131(5):615-21; Schmuth et al., 2013 . Eur J Hum Genet. 21(2): 123-33). Hair shafts are fragile and break easily due to trichorrhexis invaginata, or “bamboo hair”, resulting in short sparse hair. A predisposition to allergies, asthma, and eczema is also characteristic of NS. Ultimately, those afflicted by Netherton Syndrome often experience chronic skin inflammation, severe dehydration, and stunted growth.
  • SPINK5 Serine Protease Inhibitor Kazal-type 5
  • SPINK5 also known as Lympho-Epithelial Kazal-type-related Inhibitor (LEKTI)
  • LNKTI Lympho-Epithelial Kazal-type-related Inhibitor
  • recombinant nucleic acids e.g., recombinant herpes simplex virus genomes
  • SPINK Serine Protease Inhibitor Kazal-type polypeptides
  • viruses e.g., herpes viruses
  • pharmaceutical compositions and formulations, medicaments, and/or methods useful for remedying SPINK deficiencies and/or for treating an individual having, or at risk of developing, a SPINK-associated disorder e.g., Netherton Syndrome, atopic dermatitis, hereditary pancreatitis, tropical calcific pancreatitis, spermatogenic failure 29, etc.
  • the present inventors have shown that the recombinant viruses described herein were capable of transducing human epidermal cells, successfully expressing the encoded exogenous SPINK (RNA and protein), and that the exogenous polypeptide was appropriately secreted and was fully functional (see e.g., Example 2). Moreover, the present inventors have shown that the viruses described herein may be successfully administered either topically or intradermally in vivo without significant cytotoxicity, allowing for the encoded human SPINK polypeptide to be expressed in and localized to the appropriate region of the skin (see e.g., Example 3).
  • SPINK polypeptide e.g., human SPINK5
  • increasing, augmenting, and/or supplementing the levels of SPINK polypeptide will: 1) enhance anti-inflammatory and/or anti-microbial protection of mucous epithelia; 2) reduce transepidermal water loss (TEWL); 3) inhibit desquamation; and 4) reduce or treat skin barrier defects in the subject.
  • SPINK polypeptide e.g., human SPINK5
  • a SPINK polypeptide e.g., human SPINK5
  • a SPINK deficiency e.g., Netherton Syndrome, atopic dermatitis, etc.
  • certain aspects of the present disclosure relate to a recombinant herpes virus genome comprising one or more polynucleotides encoding a Serine Protease Inhibitor Kazal-type (SPINK) polypeptide.
  • the recombinant herpes virus genome comprises two or more polynucleotides encoding a SPINK polypeptide.
  • the recombinant herpes virus genome is replication competent.
  • the recombinant herpes virus genome is replication defective.
  • the recombinant herpes virus genome is selected from a recombinant herpes simplex virus genome, a recombinant varicella zoster virus genome, a recombinant human cytomegalovirus genome, a recombinant herpesvirus 6A genome, a recombinant herpesvirus 6B genome, a recombinant herpesvirus 7 genome, a recombinant Kaposi's sarcoma-associated herpesvirus genome, and any combinations or derivatives thereof.
  • the recombinant herpes virus genome is a recombinant herpes simplex virus genome.
  • the recombinant herpes simplex virus genome is a recombinant type 1 herpes simplex virus (HSV-1) genome, a recombinant type 2 herpes simplex virus (HSV-2) genome, or any derivatives thereof.
  • the recombinant herpes simplex virus genome is a recombinant HSV-1 genome.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation.
  • the inactivating mutation is in a herpes simplex virus gene.
  • the inactivating mutation is a deletion of the coding sequence of the herpes simplex virus gene.
  • the herpes simplex virus gene is selected from Infected Cell Protein (ICP) 0 (one or both copies), ICP4 (one or both copies), ICP22, ICP27, ICP47, thymidine kinase (tk), Long Unique Region (UL) 41, and UL55.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in one or both copies of the ICP4 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP22 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the UL41 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in one or both copies of the ICP0 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP27 gene.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the UL55 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the Joint region. In some embodiments, the recombinant herpes simplex virus genome comprises a deletion of the Joint region.
  • the recombinant herpes virus genome comprises the one or more polynucleotides encoding the SPINK polypeptide within one or more viral gene loci. In some embodiments that may be combined with any of the preceding embodiments, the recombinant herpes simplex virus genome comprises the one or more polynucleotides encoding the SPINK polypeptide within one or both of the ICP4 viral gene loci. In some embodiments that may be combined with any of the preceding embodiments, the recombinant herpes simplex virus genome comprises the one or more polynucleotides encoding the SPINK polypeptide within the ICP22 viral gene locus. In some embodiments that may be combined with any of the preceding embodiments, the recombinant herpes simplex virus genome comprises the one or more polynucleotides encoding the SPINK polypeptide within the UL41 viral gene locus.
  • the SPINK polypeptide is a human SPINK polypeptide. In some embodiments that may be combined with any of the preceding embodiments, the SPINK polypeptide is a Serine Protease Inhibitor Kazal-type 5 (SPINK5) polypeptide. In some embodiments that may be combined with any of the preceding embodiments, the SPINK polypeptide is a human SPINK5 polypeptide.
  • SPINK5 Serine Protease Inhibitor Kazal-type 5
  • the SPINK polypeptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence selected from SEQ ID NOS: 7-25.
  • the SPINK polypeptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence selected from SEQ ID NOS: 7-9.
  • the SPINK polypeptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7.
  • the SPINK polypeptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8.
  • the SPINK polypeptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9.
  • the recombinant herpes virus genome has reduced cytotoxicity when introduced into a target cell as compared to a corresponding wild-type herpes virus genome.
  • the target cell is a human cell.
  • the target cell is a cell of the epidermis and/or dermis.
  • the target cell is a keratinocyte or fibroblast.
  • herpes virus comprising any of the recombinant herpes virus genomes described herein.
  • the herpes virus is replication competent.
  • the herpes virus is replication defective.
  • the herpes virus has reduced cytotoxicity as compared to a corresponding wild-type herpes virus.
  • the herpes virus is selected from a herpes simplex virus, a varicella zoster virus, a human cytomegalovirus, a herpesvirus 6A, a herpesvirus 6B, a herpesvirus 7, a Kaposi's sarcoma-associated herpesvirus, and any combinations or derivatives thereof.
  • the herpes virus is a herpes simplex virus.
  • the herpes simplex virus is an HSV-1, an HSV-2, or any derivatives thereof.
  • the herpes simplex virus is an HSV-1.
  • compositions comprising any of the recombinant herpes virus genomes described herein and/or any of the herpes viruses described herein and a pharmaceutically acceptable excipient.
  • the pharmaceutical composition is suitable for topical, transdermal, subcutaneous, intradermal, oral, sublingual, buccal, rectal, vaginal, inhaled, intravenous, intraarterial, intramuscular, intracardiac, intraosseous, intraperitoneal, transmucosal, intravitreal, subretinal, intraarticular, peri-articular, local, epicutaneous administration, or any combinations thereof.
  • the pharmaceutical composition is suitable for topical, transdermal, subcutaneous, intradermal, and/or transmucosal administration. In some embodiments that may be combined with any of the preceding embodiments, the pharmaceutical composition is suitable for topical, transdermal, and/or intradermal administration. In some embodiments that may be combined with any of the preceding embodiments, the pharmaceutical composition is suitable for topical and/or intradermal administration. In some embodiments that may be combined with any of the preceding embodiments, the pharmaceutical composition is suitable for topical administration.
  • the pharmaceutical composition comprises a methylcellulose gel (e.g., a carboxy methylcellulose gel, a hydroxypropyl methylcellulose gel, etc.). In some embodiments that may be combined with any of the preceding embodiments, the pharmaceutical composition comprises a phosphate buffer. In some embodiments that may be combined with any of the preceding embodiments, the pharmaceutical composition comprises glycerol. In some embodiments that may be combined with any of the preceding embodiments, the pharmaceutical composition comprises a lipid carrier. In some embodiments that may be combined with any of the preceding embodiments, the pharmaceutical composition comprises a nanoparticle carrier.
  • a methylcellulose gel e.g., a carboxy methylcellulose gel, a hydroxypropyl methylcellulose gel, etc.
  • the pharmaceutical composition comprises a phosphate buffer.
  • the pharmaceutical composition comprises glycerol.
  • the pharmaceutical composition comprises a lipid carrier. In some embodiments that may be combined with any of the preceding embodiments, the pharmaceutical composition comprises a nanoparticle carrier.
  • aspects of the present disclosure relate to the use of any of the recombinant nucleic acids, herpes viruses, and/or pharmaceutical compositions described herein as a medicament.
  • aspects of the present disclosure relate to the use of any of the recombinant nucleic acids, herpes viruses, and/or pharmaceutical compositions described herein in a therapy.
  • aspects of the present disclosure relate to the use of any of the recombinant nucleic acids, herpes viruses, and/or pharmaceutical compositions described herein in the production or manufacture of a medicament for treating one or more signs or symptoms of SPINK polypeptide deficiency (e.g., Netherton Syndrome, atopic dermatitis, etc.).
  • SPINK polypeptide deficiency e.g., Netherton Syndrome, atopic dermatitis, etc.
  • the SPINK polypeptide is a SPINK5 polypeptide (e.g., a human SPINK5 polypeptide).
  • the subject is a human.
  • the subject's genome comprises a loss-of-function mutation in a SPINK5 gene.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, epicutaneously, intradermally, orally, sublingually, buccally, rectally, vaginally, intravenously, intraarterially, intramuscularly, intraosseously, intracardially, intraperitoneally, transmucosally, intravitreally, subretinally, intraarticularly, periarticularly, locally, or via inhalation to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, intradermally, or transmucosally to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically to the subject.
  • the skin of the subject is abraded prior to administration.
  • aspects of the present disclosure relate to a method of enhancing, increasing, augmenting, and/or supplementing anti-inflammatory and/or anti-microbial protection of mucous epithelia in a subject in need thereof comprising administering to the subject an effective amount of any of the herpes viruses described herein and/or any of the pharmaceutical compositions described herein.
  • the subject is a human.
  • the subject's genome comprises a loss-of-function mutation in a SPINK5 gene.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, epicutaneously, intradermally, orally, sublingually, buccally, rectally, vaginally, intravenously, intraarterially, intramuscularly, intraosseously, intracardially, intraperitoneally, transmucosally, intravitreally, subretinally, intraarticularly, periarticularly, locally, or via inhalation to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, intradermally, or transmucosally to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically to the subject.
  • the skin of the subject is abraded prior to administration.
  • aspects of the present disclosure relate to a method of repressing desquamation in a subject in need thereof comprising administering to the subject an effective amount of any of the herpes viruses described herein and/or any of the pharmaceutical compositions described herein.
  • the subject is a human.
  • the subject's genome comprises a loss-of-function mutation in a SPINK5 gene.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, epicutaneously, intradermally, orally, sublingually, buccally, rectally, vaginally, intravenously, intraarterially, intramuscularly, intraosseously, intracardially, intraperitoneally, transmucosally, intravitreally, subretinally, intraarticularly, periarticularly, locally, or via inhalation to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, intradermally, or transmucosally to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically to the subject.
  • the skin of the subject is abraded prior to administration.
  • the present disclosure relate to a method of reducing or treating a skin barrier defect in a subject in need thereof comprising administering to the subject an effective amount of any of the herpes viruses described herein and/or any of the pharmaceutical compositions described herein.
  • the skin barrier defect is transepithelial water loss (TEWL).
  • TEWL transepithelial water loss
  • the subject is a human.
  • the subject's genome comprises a loss-of-function mutation in a SPINK5 gene.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, epicutaneously, intradermally, orally, sublingually, buccally, rectally, vaginally, intravenously, intraarterially, intramuscularly, intraosseously, intracardially, intraperitoneally, transmucosally, intravitreally, subretinally, intraarticularly, periarticularly, locally, or via inhalation to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, intradermally, or transmucosally to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically to the subject.
  • the skin of the subject is abraded prior to administration.
  • aspects of the present disclosure relate to a method of providing prophylactic, palliative, or therapeutic relief of one or more signs or symptoms of Netherton Syndrome (NS) in a subject in need thereof comprising administering to the subject an effective amount of any of the herpes viruses described herein and/or any of the pharmaceutical compositions described herein.
  • NS Netherton Syndrome
  • the one or more signs or symptoms of NS are selected from defective keratinization, a defective skin barrier, chronic skin inflammation, universal pruritus, severe dehydration, stunted growth, trichorrhexis invaginata and/or trichorrhexis nodosa, leaking fluid from the skin, development of ring-like lesions on the skin, eczema, increased susceptibility to infection, recurrent skin infections, increased susceptibility to allergy, development of scaly/reddish skin, development of ichthyosis linearis circumflexa and/or ichthyosiform erythroderma, altered immunoglobulin levels, immature natural killer cells having reduced lytic function, difficulty regulating body temperature, and any combinations thereof.
  • the one or more sign or symptoms of NS are selected from defective keratinization, a defective skin barrier, recurrent skin infections, congenital ichthyosiform erythroderma, ichthyosis linearis circumflexa, trichorrhexis invaginata, chronic skin inflammation, and any combinations thereof.
  • the subject is a human.
  • the subject's genome comprises a loss-of-function mutation in a SPINK5 gene.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, epicutaneously, intradermally, orally, sublingually, buccally, rectally, vaginally, intravenously, intraarterially, intramuscularly, intraosseously, intracardially, intraperitoneally, transmucosally, intravitreally, subretinally, intraarticularly, periarticularly, locally, or via inhalation to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, intradermally, or transmucosally to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, or intradermally to the subject. In some embodiments that may be combined with any of the preceding embodiments, the herpes virus and/or pharmaceutical composition is administered topically or intradermally to the subject. In some embodiments that may be combined with any of the preceding embodiments, the herpes virus and/or pharmaceutical composition is administered intradermally to the subject. In some embodiments that may be combined with any of the preceding embodiments, the herpes virus and/or pharmaceutical composition is administered topically to the subject. In some embodiments that may be combined with any of the preceding embodiments, the skin of the subject is abraded prior to administration.
  • aspects of the present disclosure relate to a method of providing prophylactic, palliative, or therapeutic relief of one or more signs or symptoms of atopic dermatitis in a subject in need thereof comprising administering to the subject an effective amount of any of the herpes viruses described herein and/or any of the pharmaceutical compositions described herein.
  • the one or more signs or symptoms of atopic dermatitis are selected from itchy skin, dry skin, red to brownish-grey patches on the skin, small raised bumps on the skin, thickened skin, cracked skin, scaly skin, swollen skin, weeping sores, skin infections, eyelid dermatitis, cataracts, and any combinations thereof.
  • the subject is a human. In some embodiments that may be combined with any of the preceding embodiments, the subject's genome comprises a loss-of-function mutation in a SPINK5 gene.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, epicutaneously, intradermally, orally, sublingually, buccally, rectally, vaginally, intravenously, intraarterially, intramuscularly, intraosseously, intracardially, intraperitoneally, transmucosally, intravitreally, subretinally, intraarticularly, periarticularly, locally, or via inhalation to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, subcutaneously, intradermally, or transmucosally to the subject.
  • the herpes virus and/or pharmaceutical composition is administered topically, transdermally, or intradermally to the subject. In some embodiments that may be combined with any of the preceding embodiments, the herpes virus and/or pharmaceutical composition is administered topically or intradermally to the subject. In some embodiments that may be combined with any of the preceding embodiments, the herpes virus and/or pharmaceutical composition is administered intradermally to the subject. In some embodiments that may be combined with any of the preceding embodiments, the herpes virus and/or pharmaceutical composition is administered topically to the subject. In some embodiments that may be combined with any of the preceding embodiments, the skin of the subject is abraded prior to administration.
  • aspects of the present disclosure relate to an article of manufacture or kit comprising any of the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations described herein and instructions for administration thereof.
  • FIGS. 1A-I show schematics of wild-type and modified herpes simplex virus genomes.
  • FIG. 1A shows a wild-type herpes simplex virus genome.
  • FIG. 1B shows a modified herpes simplex virus genome comprising deletions of the coding sequence of ICP4 (both copies), with an expression cassette containing a nucleic acid encoding a human SPINK5 polypeptide integrated at each of the ICP4 loci.
  • FIG. 1C shows a modified herpes simplex virus genome comprising deletions of the coding sequences of ICP4 (both copies) and ICP22, with an expression cassette containing a nucleic acid encoding a human SPINK5 polypeptide integrated at each of the ICP4 loci.
  • FIG. 1A shows a wild-type herpes simplex virus genome.
  • FIG. 1B shows a modified herpes simplex virus genome comprising deletions of the coding sequence of ICP4 (both copies), with an expression cassette containing a nu
  • FIG. 1D shows a modified herpes simplex virus genome comprising deletions of the coding sequences of ICP4 (both copies) and ICP22, with an expression cassette containing a nucleic acid encoding a human SPINK5 polypeptide integrated at the ICP22 locus.
  • FIG. 1E shows a modified herpes simplex virus genome comprising deletions of the coding sequences of ICP4 (both copies) and UL41, with an expression cassette containing a nucleic acid encoding a human SPINK5 polypeptide integrated at each of the ICP4 loci.
  • FIG. 1F shows a modified herpes simplex virus genome comprising deletions of the coding sequences of ICP4 (both copies) and UL41, with an expression cassette containing a nucleic acid encoding a human SPINK5 polypeptide integrated at the UL41 locus.
  • FIG. 1G shows a modified herpes simplex virus genome comprising deletions of the coding sequences of ICP4 (both copies), ICP22, and UL41, with an expression cassette containing a nucleic acid encoding a human SPINK5 polypeptide integrated at each of the ICP4 loci.
  • FIG. 1H shows a modified herpes simplex virus genome comprising deletions of the coding sequences of ICP4 (both copies), ICP22, and UL41, with an expression cassette containing a nucleic acid encoding a human SPINK5 polypeptide integrated at the UL41 locus.
  • FIG. 1I shows a modified herpes simplex virus genome comprising deletions of the coding sequences of ICP4 (both copies), ICP22, and UL41, with an expression cassette containing a nucleic acid encoding a human SPINK5 polypeptide integrated at the ICP22 locus.
  • FIGS. 2A-D show human SPINK5 nucleic acid and protein analyses in immortalized normal keratinocytes infected with HSV-S5.
  • FIG. 2A shows the levels of codon-optimized human SPINK5 DNA present in immortalized normal keratinocytes 48 hours after infection with HSV-S5 at the indicated MOIs, as determined by qPCR analysis.
  • FIG. 2B shows the levels of codon-optimized human SPINK5 transcripts present in immortalized normal keratinocytes 48 hours after infection with HSV-S5 at the indicated MOIs, as determined by qRT-PCR analysis.
  • FIG. 1A shows the levels of codon-optimized human SPINK5 DNA present in immortalized normal keratinocytes 48 hours after infection with HSV-S5 at the indicated MOIs, as determined by qRT-PCR analysis.
  • FIG. 2C shows western blot analysis of human SPINK5 protein expression in immortalized normal keratinocytes 48 hours after infection with HSV-S5 at the indicated MOIs. GAPDH was used as a loading control.
  • FIG. 2D shows representative immunofluorescence images of human SPINK5 protein expression in immortalized normal keratinocytes 48 hours after infection with HSV-S5 at the indicated MOIs. DAPI staining was used to visualize nuclei. For all experiments, uninfected (mock) cells were used as a negative control.
  • FIG. 3 shows the concentration of human SPINK5 secreted into the supernatant of cultured immortalized normal keratinocytes 48 hours after infection with HSV-S5 at the indicated MOIs, as assessed by ELISA.
  • Cell supernatant collected from uninfected (mock) immortalized normal keratinocytes was used as a negative control.
  • FIG. 4 shows the percent inhibition in proteolytic activity of recombinant human Kallikrein 5 (KLK5) after incubation with cell culture supernatants collected from immortalized normal keratinocytes infected with HSV-S5 at the indicated MOIs, as assessed in a fluorometric assay employing a synthetic, non-natural peptide substrate of human KLK5.
  • Cell supernatant collected from uninfected (mock) immortalized normal keratinocytes was used as a negative control. Data is presented as the average ⁇ SEM.
  • FIGS. 5A-F show nucleic acid and protein analyses, as well as histology, of skin biopsies harvested from control- or HSV-S5-treated BALB/c mice.
  • FIG. 5A shows the levels of human SPINK5 DNA present in the skin of immunocompetent animals harvested 48 hours after topical application of HSV-S5 or vehicle control, as assessed by qPCR analysis.
  • FIG. 5B shows the levels of human SPINK5 transcripts present in the skin of immunocompetent animals harvested 48 hours after topical application of HSV-S5 or vehicle control, as assessed by qRT-PCR analysis.
  • FIG. 5A shows the levels of human SPINK5 DNA present in the skin of immunocompetent animals harvested 48 hours after topical application of HSV-S5 or vehicle control, as assessed by qRT-PCR analysis.
  • FIG. 5C shows the levels of human SPINK5 DNA present in the skin of immunocompetent animals harvested 48 hours after intradermal injection of HSV-S5 or vehicle control, as assessed by qPCR analysis.
  • FIG. 5D shows the levels of human SPINK5 transcripts present in the skin of immunocompetent animals harvested 48 hours after intradermal injection of HSV-S5 or vehicle control, as assessed by qRT-PCR analysis.
  • vehicle control data is presented as the average of two tissue samples (two replicates/tissue sample) ⁇ SEM
  • HSV-S5 data is presented as the average of six tissue samples (two replicates/tissue sample) ⁇ SEM.
  • FIG. 5E shows representative immunofluorescence images of human SPINK5 and mouse filaggrin protein expression in skin biopsies harvested from BALB/c mice 48 hours after topical application of HSV-S5 or vehicle control. DAPI staining was used to visualize nuclei.
  • FIG. 5F shows representative histology of mouse skin biopsies harvested from BALB/c mice 48 hours after topical application of HSV-S5 or vehicle control.
  • the present disclosure relates to recombinant nucleic acids (e.g., recombinant herpes viral genomes) comprising one or more polynucleotides encoding a Serine Protease Inhibitor Kazal-type (SPINK) polypeptide (e.g., a human SPINK5 polypeptide), and/or use of these recombinant nucleic acids in viruses (e.g., herpes viruses), compositions, formulations, medicaments, and/or methods in order to supplement or treat SPINK gene deficiencies (e.g., in a subject whose genome naturally harbors a loss-of-function and/or pathogenic variant of a SPINK gene), and/or provide medical intervention to a subject in need thereof (e.g., to provide prophylactic, palliative, and/or therapeutic relief to one or more diseases or disorders arising from a SPINK gene deficiency (e.g., Netherton Syndrome, atopic dermatitis).
  • nucleic acids, viruses, compositions, formulations, medicaments, and/or methods described herein will help to treat the existing skin abnormalities in individuals suffering from Netherton Syndrome and/or atopic dermatitis, as well as prevent or delay reformation of skin abnormalities in treated subjects.
  • the term “and/or” may include any and all combinations of one or more of the associated listed items.
  • the term “a and/or b” may refer to “a alone”, “b alone”, “a or b”, or “a and b”;
  • the term “a, b, and/or c” may refer to “a alone”, “b alone”, “c alone”, “a or b”, “a or c”, “b or c”, “a, b, or c”, “a and b”, “a and c”, or “a, b, and c”; etc.
  • the term “about” refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.
  • polynucleotide As used herein, the terms “polynucleotide”, “nucleic acid sequence”, “nucleic acid”, and variations thereof shall be generic to polydeoxyribonucleotides (containing 2-deoxy-D-ribose), to polyribonucleotides (containing D-ribose), to any other type of polynucleotide that is an N-glycoside of a purine or pyrimidine base, and to other polymers containing non-nucleotidic backbones, provided that the polymers contain nucleobases in a configuration that allows for base pairing and base stacking, as found in DNA and RNA.
  • these terms include known types of nucleic acid sequence modifications, for example, substitution of one or more of the naturally occurring nucleotides with an analog, and inter-nucleotide modifications.
  • a nucleic acid is “operatively linked” or “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • operatively linked or “operably linked” means that the DNA sequences being linked are contiguous.
  • an expression vector refers to discrete elements that are used to introduce heterologous nucleic acids into cells for either expression or replication thereof.
  • An expression vector includes vectors capable of expressing nucleic acids that are operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such nucleic acids.
  • an expression vector may refer to a DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the nucleic acids.
  • Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and those that remain episomal or those which integrate into the host cell genome.
  • an “open reading frame” or “ORF” refers to a contiguous stretch of nucleic acids, either DNA or RNA, that encode a protein or polypeptide.
  • the nucleic acid comprises a translation start signal or initiation codon, such as ATG or AUG, and a termination codon.
  • an “untranslated region” or “UTR” refers to untranslated nucleic acids at the 5′ and/or 3′ ends of an open reading frame.
  • the inclusion of one or more UTRs in a polynucleotide may affect post-transcriptional regulation, mRNA stability, and/or translation of the polynucleotide.
  • transgene refers to a polynucleotide that is capable of being transcribed into RNA and translated and/or expressed under appropriate conditions, after being introduced into a cell. In some embodiments, it confers a desired property to a cell into which it was introduced, or otherwise leads to a desired therapeutic or diagnostic outcome.
  • polypeptide As used herein, the terms “polypeptide,” “protein,” and “peptide” are used interchangeably and may refer to a polymer of two or more amino acids.
  • a “subject”, “host”, or an “individual” refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, as well as animals used in research, such as mice, rats, hamsters, rabbits, and non-human primates, etc.
  • the mammal is human.
  • the terms “pharmaceutical formulation” or “pharmaceutical composition” refer to a preparation which is in such a form as to permit the biological activity of the active ingredient(s) to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the composition or formulation would be administered.
  • “Pharmaceutically acceptable” excipients e.g., vehicles, additives
  • an “effective amount” is at least the minimum amount required to affect a measurable improvement or prevention of one or more symptoms of a particular disorder.
  • An “effective amount” may vary according to factors such as the disease state, age, sex, and weight of the patient.
  • An effective amount is also one in which any toxic or detrimental effects of the treatment are outweighed by the therapeutically beneficial effects.
  • beneficial or desired results include results such as eliminating or reducing the risk, lessening the severity, or delaying the onset of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease.
  • beneficial or desired results include clinical results such as decreasing one or more symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications used to treat symptoms of the disease, delaying the progression of the disease, and/or prolonging survival.
  • An effective amount can be administered in one or more administrations.
  • an effective amount of a recombinant nucleic acid, virus, and/or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly.
  • an effective amount of a recombinant nucleic acid, virus, and/or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition.
  • an “effective amount” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.
  • treatment refers to clinical intervention designed to alter the natural course of the individual or cell being treated during the course of clinical pathology. Desirable effects of treatment include decreasing the rate of disease/disorder/defect progression, ameliorating or palliating the disease/disorder/defect state, and remission or improved prognosis. For example, an individual is successfully “treated” if one or more symptoms associated with Netherton Syndrome and/or atopic dermatitis are mitigated or eliminated.
  • the term “delaying progression of” a disease/disorder/defect refers to deferring, hindering, slowing, retarding, stabilizing, and/or postponing development of the disease/disorder/defect. This delay can be of varying lengths or time, depending on the history of the disease/disorder/defect and/or the individual being treated. As is evident to one of ordinary skill in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease.
  • Certain aspects of the present disclosure relate to recombinant nucleic acids (e.g., isolated recombinant nucleic acids) comprising one or more (e.g., one or more, two or more, three or more, four or more, five or more, ten or more, etc.) polynucleotides encoding a Serine Protease Inhibitor Kazal-type (SPINK) polypeptide.
  • the recombinant nucleic acid comprises one polynucleotide encoding a SPINK polypeptide.
  • the recombinant nucleic acid comprises two polynucleotides encoding a SPINK polypeptide.
  • the SPINK polypeptide is a human SPINK polypeptide. In some embodiments, the SPINK polypeptide is a Serine Protease Inhibitor Kazal-type 5 (SPINK5) polypeptide. In some embodiments, the SPINK5 polypeptide is a human SPINK5 polypeptide.
  • the recombinant nucleic acid is a vector. In some embodiments, the recombinant nucleic acid is a viral vector. In some embodiments, the recombinant nucleic acid is a herpes viral vector. In some embodiments, the recombinant nucleic acid is a herpes simplex virus amplicon. In some embodiments, the recombinant nucleic acid is a recombinant herpes virus genome. In some embodiments, the recombinant nucleic acid is a recombinant herpes simplex virus genome. In some embodiments, the recombinant nucleic acid is a recombinant type 1 herpes simplex virus (HSV-1) genome.
  • HSV-1 herpes simplex virus
  • the present disclosure relates to a recombinant nucleic acid comprising one or more polynucleotides comprising the coding sequence of a SPINK gene, or portions thereof (e.g., the coding sequence corresponding to one or more Kazal-type domains resulting from proteolytic cleavage (e.g., via furin cleavage) of a full-length SPINK polypeptide).
  • any suitable SPINK gene (including any isoform thereof) known in the art may be encoded by a polynucleotide of the present disclosure, including, for example, a SPINK1 gene (e.g., a human SPINK1 gene (see e.g., NCBI Gene ID: 6690)), a SPINK2 gene (e.g., a human SPINK2 gene (see e.g., NCBI Gene ID: 6691)), a SPINK4 gene (e.g., a human SPINK4 gene (see e.g., NCBI Gene ID: 27920)), a SPINK5 gene (e.g., a human SPINK5 gene (see e.g., NCBI Gene ID: 11005)), a SPINK6 gene (e.g., a human SPINK6 gene (see e.g., NCBI Gene ID: 404203)), a SPINK7 gene (e.g., a human SPINK7
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of any SPINK gene (and/or coding sequences thereof) described herein or known in the art.
  • one or more polynucleotides of the present disclosure comprises the coding sequence of a human SPINK gene.
  • a polynucleotide of the present disclosure comprises a codon-optimized variant of any SPINK gene described herein or known in the art.
  • use of a codon-optimized variant of a SPINK gene increases stability and/or yield of heterologous expression (RNA and/or protein) of the encoded SPINK polypeptide in a target cell (e.g., a target human cell such as a human keratinocyte or fibroblast), as compared to the stability and/or yield of heterologous expression of a corresponding non-codon-optimized, wild-type sequence.
  • Any suitable method known in the art for performing codon optimization of a sequence for expression in one or more target cells may be used, including, for example, by the methods described by Fath et al. (PLoS One. 2011 Mar. 3; 6(3): e17596).
  • the present disclosure relates to a recombinant nucleic acid comprising one or more polynucleotides comprising the coding sequence of a SPINK5 gene (e.g., a human SPINK5 gene), or portions thereof (e.g., the coding sequence corresponding to one or more Kazal-type domains resulting from proteolytic cleavage (e.g., via furin cleavage) of a full-length SPINK5 polypeptide).
  • a SPINK5 gene e.g., a human SPINK5 gene
  • portions thereof e.g., the coding sequence corresponding to one or more Kazal-type domains resulting from proteolytic cleavage (e.g., via furin cleavage) of a full-length SPINK5 polypeptide.
  • any suitable SPINK5 gene (including any isoform thereof) known in the art may be encoded by a polynucleotide of the present disclosure, including, for example, a human SPINK5 gene (see e.g., NCBI Gene ID: 11005; SEQ ID NOS: 1, 3, or 5), a chimpanzee SPINK5 gene (see e.g., NCBI Gene ID: 462173), a mouse SPINK5 gene (see e.g., NCBI Gene ID: 72432), a rat SPINK5 gene (see e.g., NCBI Gene ID: 361319), a dog SPINK5 gene (see e.g., NCBI Gene ID: 478055), a cow SPINK5 gene (see e.g., NCBI Gene ID: 526637), a horse SPINK5 gene (see e.g., NCBI Gene ID: 100071873), a pig SPINK5 gene (see e.g., NCBI Gene
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of any SPINK5 gene (and/or the coding sequences thereof) described herein or known in the art.
  • Methods of identifying SPINK5 gene homologs/orthologs from additional species are known to one of ordinary skill in the art, including, for example, using a nucleic acid sequence alignment program such as the BLAST® blastn suite.
  • a polynucleotide of the present disclosure comprises a codon-optimized variant of any SPINK5 gene described herein or known in the art (see e.g., SEQ ID NOS: 2, 4, 6, or 26).
  • use of a codon-optimized variant of a SPINK5 gene e.g., a codon-optimized variant of a human SPINK5 gene
  • a target cell e.g., a target human cell such as a human keratinocyte or fibroblast
  • Any suitable method known in the art for performing codon optimization of a sequence for expression in one or more target cells may be used, including, for example, by the methods described by Fath et al. (PLoS One. 2011 Mar. 3; 6(3): e17596).
  • one or more polynucleotides of the present disclosure comprises the coding sequence of a human SPINK5 gene (or a codon-optimized variant thereof), or portions thereof (e.g., the coding sequence corresponding to one or more Kazal-type domains resulting from proteolytic cleavage (e.g., via human furin cleavage) of a full-length human SPINK5 polypeptide).
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to a sequence selected from SEQ ID NOS: 1-6 and 26.
  • a polynucleotide of the present disclosure comprises a sequence selected from SEQ ID NOS: 1-6 and 26.
  • a polynucleotide of the present disclosure comprises a sequence selected from SEQ ID NOS: 2, 4, 6, and 26.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a 5′ truncation, a 3′ truncation, or a fragment of the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • the 5′ truncation, 3′ truncation, or fragment of the sequence of SEQ ID NO: 1 or SEQ ID NO: 2 is a polynucleotide that has at least 25, at least 50, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, or at least 350, at least 400, at least 450, at least 500, at least 750, at least 1000, at least 1250, at least 1500, at least 1750, at least 2000, at least 2250, at least 2500, at least 2750, at least 3000, at least 3250, but fewer than 3285 consecutive nucleotides of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 1-3282 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 1-3282 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 82-198 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 82-198 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 271-459 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 271-459 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 463-648 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 463-648 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 9′7%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 655-855 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 655-855 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 871-1056 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 871-1056 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 1081-1269 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 1081-1269 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 1291-1467 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 1291-1467 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 1468-1653 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 1468-1653 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 1681-1866 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 1681-1866 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 1876-2064 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 1876-2064 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 2101-2271 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 2101-2271 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 2302-2490 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 2302-2490 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 2527-2715 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 2527-2715 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 2728-3003 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 2728-3003 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 3049-3234 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 3049-3234 of SEQ ID NO: 1 or SEQ ID NO: 2.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of SEQ ID NO: 3 or SEQ ID NO: 4.
  • a polynucleotide of the present disclosure comprises the sequence of SEQ ID NO: 3 or SEQ ID NO: 4.
  • a polynucleotide of the present disclosure comprises the sequence of SEQ ID NO: 4.
  • a polynucleotide of the present disclosure comprises a 5′ truncation, a 3′ truncation, or a fragment of the sequence of SEQ ID NO: 3 or SEQ ID NO: 4.
  • the 5′ truncation, 3′ truncation, or fragment of the sequence of SEQ ID NO: 3 or SEQ ID NO: 4 is a polynucleotide that has at least 25, at least 50, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, or at least 350, at least 400, at least 450, at least 500, at least 750, at least 1000, at least 1250, at least 1500, at least 1750, at least 2000, at least 2250, at least 2500, at least 2750, but fewer than 2751 consecutive nucleotides of SEQ ID NO: 3 or SEQ ID NO: 4.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 1-2748 of SEQ ID NO: 3 or SEQ ID NO: 4.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 1-2748 of SEQ ID NO: 3 or SEQ ID NO: 4.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 26.
  • a polynucleotide of the present disclosure comprises the sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 26.
  • a polynucleotide of the present disclosure comprises the sequence of SEQ ID NO: 6.
  • a polynucleotide of the present disclosure comprises the sequence of SEQ ID NO: 26.
  • a polynucleotide of the present disclosure comprises a 5′ truncation, a 3′ truncation, or a fragment of the sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 26.
  • the 5′ truncation, 3′ truncation, or fragment of the sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 26 is a polynucleotide that has at least 25, at least 50, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, or at least 350, at least 400, at least 450, at least 500, at least 750, at least 1000, at least 1250, at least 1500, at least 1750, at least 2000, at least 2250, at least 2500, at least 2750, at least 3000, but fewer than 3195 consecutive nucleotides of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 26.
  • a polynucleotide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence of nucleic acids 1-3192 of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 26.
  • a polynucleotide of the present disclosure comprises the sequence of nucleic acids 1-3192 of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 26.
  • a polynucleotide of the present disclosure encoding a SPINK polypeptide may further encode additional coding and non-coding sequences.
  • additional coding and non-coding sequences may include, but are not limited to, sequences encoding additional polypeptide tags (e.g., encoded in-frame with the SPINK protein in order to produce a fusion protein), introns (e.g., native, modified, or heterologous introns), 5′ and/or 3′ UTRs (e.g., native, modified, or heterologous 5′ and/or 3′ UTRs), and the like.
  • suitable polypeptide tags may include, but are not limited, to any combination of purification tags, such as his-tags, flag-tags, maltose binding protein and glutathione-S-transferase tags, detection tags, such as tags that may be detected photometrically (e.g., green fluorescent protein, red fluorescent protein, etc.) and tags that have a detectable enzymatic activity (e.g., alkaline phosphatase, etc.), tags containing secretory sequences, signal sequences, leader sequences, and/or stabilizing sequences, protease cleavage sites (e.g., furin cleavage sites, TEV cleavage sites, Thrombin cleavage sites, etc.), and the like.
  • purification tags such as his-tags, flag-tags, maltose binding protein and glutathione-S-transferase tags
  • detection tags such as tags that may be detected photometrically (e.g., green fluorescent protein, red fluorescent protein, etc.) and tags
  • the 5′ and/or 3′UTRs increase the stability, localization, and/or translational efficiency of the polynucleotides. In some embodiments, the 5′ and/or 3′UTRs improve the level and/or duration of protein expression. In some embodiments, the 5′ and/or 3′UTRs include elements (e.g., one or more miRNA binding sites, etc.) that may block or reduce off-target expression (e.g., inhibiting expression in specific cell types (e.g., neuronal cells), at specific times in the cell cycle, at specific developmental stages, etc.).
  • off-target expression e.g., inhibiting expression in specific cell types (e.g., neuronal cells), at specific times in the cell cycle, at specific developmental stages, etc.
  • the 5′ and/or 3′UTRs include elements (e.g., one or more miRNA binding sites, etc.) that may enhance effector protein expression in specific cell types (such as human keratinocytes and/or fibroblasts).
  • a polynucleotide of the present disclosure is operably linked to one or more (e.g., one or more, two or more, three or more, four or more, five or more, ten or more, etc.) regulatory sequences.
  • regulatory sequence may include enhancers, insulators, promoters, and other expression control elements (e.g., polyadenylation signals).
  • enhancer(s) known in the art may be used, including, for example, enhancer sequences from mammalian genes (such as globin, elastase, albumin, ⁇ -fetoprotein, insulin and the like), enhancer sequences from a eukaryotic cell virus (such as SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, adenovirus enhancers, and the like), and any combinations thereof.
  • mammalian genes such as globin, elastase, albumin, ⁇ -fetoprotein, insulin and the like
  • enhancer sequences from a eukaryotic cell virus such as SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, adenovirus enhancers, and
  • insulator(s) known in the art may be used, including, for example, herpes simplex virus (HSV) chromatin boundary (CTRL/CTCF-binding/insulator) elements CTRL1 and/or CTRL2, chicken hypersensitive site 4 insulator (cHS4), human HNRPA2B1-CBX3 ubiquitous chromatin opening element (UCOE), the scaffold/matrix attachment region (S/MAR) from the human interferon beta gene (IFNB1), and any combinations thereof.
  • HSV herpes simplex virus
  • CTRL/CTCF-binding/insulator CTRL1 and/or CTRL2
  • CHS4 CHS4
  • cHS4 chicken hypersensitive site 4 insulator
  • UCOE human HNRPA2B1-CBX3 ubiquitous chromatin opening element
  • S/MAR scaffold/matrix attachment region from the human interferon beta gene
  • any suitable promoter e.g., suitable for transcription in mammalian host cells
  • suitable promoters including, for example, promoters obtained from the genomes of viruses (such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus, Simian Virus 40 (SV40), and the like), promoters from heterologous mammalian genes (such as the actin promoter (e.g., the ⁇ -actin promoter), a ubiquitin promoter (e.g., a ubiquitin C (UbC) promoter), a phosphoglycerate kinase (PGK) promoter, an immunoglobulin promoter, from heat-shock protein promoters, and the like), promoters from native and/or homologous mammalian genes (e.
  • a polynucleotide of the present disclosure is operably linked to one or more heterologous promoters.
  • the one or more heterologous promoters are one or more of constitutive promoters, tissue-specific promoters, temporal promoters, spatial promoters, inducible promoters and repressible promoters.
  • the one or more heterologous promoters are one or more of the human cytomegalovirus (HCMV) immediate early promoter, the human elongation factor-1 (EF1) promoter, the human ⁇ -actin promoter, the human UbC promoter, the human PGK promoter, the synthetic CAGG promoter, and any combinations thereof.
  • a polynucleotide of the present disclosure is operably linked to an HCMV promoter.
  • a recombinant nucleic acid of the present disclosure does not comprise a polynucleotide comprising the coding sequence of (e.g., a transgene encoding) a Collagen alpha-1 (VII) chain polypeptide (COLT).
  • a recombinant nucleic acid of the present disclosure does not comprise a polynucleotide comprising the coding sequence of (e.g., a transgene encoding) a Lysyl hydroxylase 3 polypeptide (LH3).
  • a recombinant nucleic acid of the present disclosure does not comprise a polynucleotide comprising the coding sequence of (e.g., a transgene encoding) a Keratin type I cytoskeletal 17 polypeptide (KRT17).
  • a recombinant nucleic acid of the present disclosure does not comprise a polynucleotide comprising the coding sequence of (e.g., a transgene encoding) a transglutaminase (TGM) polypeptide (e.g., a human transglutaminase polypeptide such as a human TGM1 polypeptide).
  • TGM transglutaminase
  • a recombinant nucleic acid of the present disclosure does not comprise a polynucleotide comprising the coding sequence of (e.g., a transgene encoding) a cosmetic protein (e.g., collagen proteins, fibronectins, elastins, lumicans, vitronectins/vitronectin receptors, laminins, neuromodulators, fibrillins, additional dermal extracellular matrix proteins, etc.).
  • a cosmetic protein e.g., collagen proteins, fibronectins, elastins, lumicans, vitronectins/vitronectin receptors, laminins, neuromodulators, fibrillins, additional dermal extracellular matrix proteins, etc.
  • a recombinant nucleic acid of the present disclosure does not comprise a polynucleotide comprising the coding sequence of (e.g., a transgene encoding) an antibody (e.g., a full-length antibody, an antibody fragments, etc.). In some embodiments, a recombinant nucleic acid of the present disclosure does not comprise a polynucleotide comprising the coding sequence of (e.g., a transgene encoding) a Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide, and/or any chimeric polypeptides thereof.
  • VIP Collagen alpha-1
  • a recombinant nucleic acid of the present disclosure does not comprise a polynucleotide comprising the coding sequence of (e.g., a transgene encoding) a Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide, a transglutaminase (TGM) polypeptide, a cosmetic protein, an antibody, and/or any chimeric polypeptides thereof.
  • a polynucleotide comprising the coding sequence of (e.g., a transgene encoding) a Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide, a transglutaminase (TGM) polypeptide, a cosmetic protein, an antibody, and/or any chimeric polypeptides thereof.
  • the present disclosure relates to one or more polynucleotides encoding a SPINK polypeptide, or any portions thereof (e.g., the amino acid sequence of one or more Kazal-type domains resulting from proteolytic cleavage (e.g., via furin cleavage) of a full-length SPINK polypeptide).
  • SPINK polypeptide (or portions thereof) known in the art may be encoded by a polynucleotide of the present disclosure, including, for example, a SPINK1 polypeptide (e.g., a human SPINK1 polypeptide (see e.g., UniProt accession number: P00995)), a SPINK2 polypeptide (e.g., a human SPINK2 polypeptide (see e.g., UniProt accession number: P20155)), a SPINK4 polypeptide (e.g., a human SPINK4 polypeptide (see e.g., UniProt accession number: O60575)), a SPINK5 polypeptide (e.g., a human SPINK5 polypeptide (see e.g., UniProt accession number: Q9NQ38)), a SPINK6 polypeptide (e.g., a human SPINK6 polypeptide (see e.g.,
  • a SPINK polypeptide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of any SPINK polypeptide described herein or known in the art.
  • Methods of identifying SPINK polypeptide homologs/orthologs from additional species are known to one of ordinary skill in the art, including, for example, using an amino acid sequence alignment program such as the BLAST® blastp suite or OrthoDB.
  • the SPINK polypeptide is a human SPINK polypeptide.
  • the present disclosure relates to one or more polynucleotides encoding a SPINK5 polypeptide (e.g., SEQ ID NOS: 7-9), or any portions thereof (e.g., the amino acid sequence of one or more Kazal-type domains resulting from proteolytic cleavage (e.g., via furin cleavage) of a full-length SPINK5 polypeptide (e.g., SEQ ID NOS: 10-25)).
  • a SPINK5 polypeptide e.g., SEQ ID NOS: 7-9
  • any portions thereof e.g., the amino acid sequence of one or more Kazal-type domains resulting from proteolytic cleavage (e.g., via furin cleavage) of a full-length SPINK5 polypeptide (e.g., SEQ ID NOS: 10-25)
  • any suitable SPINK5 polypeptide (or portions thereof) known in the art may be encoded by a polynucleotide of the present disclosure, including, for example, a human SPINK5 polypeptide (see e.g., UniProt accession number: 11005), a chimpanzee SPINK5 polypeptide (see e.g., UniProt accession number: 462173), a mouse SPINK5 polypeptide (see e.g., UniProt accession number: Q5K5D4), a rat SPINK5 polypeptide (see e.g., UniProt accession number: D3ZET2), a dog SPINK5 polypeptide (see e.g., UniProt accession number: F1PR80), a cow SPINK5 polypeptide (see e.g., UniProt accession number: F1MJH0), a horse SPINK5 polypeptide (see e.g., UniProt accession number: B
  • a SPINK5 polypeptide of the present disclosure comprises a sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of any SPINK5 polypeptide described herein or known in the art.
  • Methods of identifying SPINK5 polypeptide homologs/orthologs from additional species are known to one of ordinary skill in the art, including, for example, using an amino acid sequence alignment program such as the BLAST® blastp suite or OrthoDB.
  • a SPINK5 polypeptide of the present disclosure is a human SPINK5 polypeptide, or portions thereof (e.g., a polypeptide comprising the amino acid sequence corresponding to one or more Kazal-type domains resulting from proteolytic cleavage (e.g., via human furin cleavage) of a full-length human SPINK5 polypeptide).
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes a polypeptide comprising an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a sequence selected from SEQ ID NOS: 7-25.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes a polypeptide comprising an amino acid sequence selected from SEQ ID NOS: 7-25.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes a polypeptide comprising an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a sequence selected from SEQ ID NOS: 7-9.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encode
  • a SPINK5 polypeptide of the present disclosure comprises, consists essentially of, or consists of a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence selected from SEQ ID NOS: 7-25.
  • a SPINK5 polypeptide of the present disclosure comprises, consists essentially of, or consists of a sequence selected from SEQ ID NOS: 7-25.
  • a SPINK5 polypeptide of the present disclosure comprises, consists essentially of, or consists of a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence selected from SEQ ID NOS: 7-9.
  • a SPINK5 polypeptide of the present disclosure comprises, consists essentially of, or consists of a sequence selected from SEQ ID NOS: 7-9.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes a polypeptide comprising an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 7.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 7.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes an N-terminal truncation, a C-terminal truncation, or a fragment of the amino acid sequence of SEQ ID NO: 7.
  • N-terminal truncations, C-terminal truncations, or fragments may comprise at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 30, at least 40, at least 50, at least 75, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, but fewer than 1094, consecutive amino acids of SEQ ID NO: 7.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes a polypeptide comprising an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 8.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 8.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes an N-terminal truncation, a C-terminal truncation, or a fragment of the amino acid sequence of SEQ ID NO: 8.
  • N-terminal truncations, C-terminal truncations, or fragments may comprise at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 30, at least 40, at least 50, at least 75, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, but fewer than 916, consecutive amino acids of SEQ ID NO: 8.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes a polypeptide comprising an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 9.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 9.
  • a polynucleotide encoding a human SPINK5 polypeptide is a polynucleotide that encodes an N-terminal truncation, a C-terminal truncation, or a fragment of the amino acid sequence of SEQ ID NO: 9.
  • N-terminal truncations, C-terminal truncations, or fragments may comprise at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 30, at least 40, at least 50, at least 75, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, but fewer than 1064, consecutive amino acids of SEQ ID NO: 9.
  • a polynucleotide of the present disclosure encodes a Kazal-type domain derived from a human SPINK5 polypeptide (e.g., a Kazal-type domain resulting from proteolytic cleavage (e.g., via furin cleavage) of human SPINK5).
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 10.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 10.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 11.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 11.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 12.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 12.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 13.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 13.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 14.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 14.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 15.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 15.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 16.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 16.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 17.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 17.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 18.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 18.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 19.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 19.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 20.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 20.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 21.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 21.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 22.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 22.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 23.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 23.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 24.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 24.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO: 25.
  • a SPINK5 polypeptide of the present disclosure comprises or consists of the amino acid sequence of SEQ ID NO: 25.
  • a polynucleotide of the present disclosure encoding a SPINK polypeptide expresses the SPINK polypeptide when the polynucleotide is delivered into one or more target cells of a subject.
  • expression of the SPINK polypeptide e.g., a SPINK5 polypeptide
  • enhances, increases, augments, and/or supplements the levels, function, and/or activity of a SPINK polypeptide in one or more target cells of a subject e.g., as compared to prior to expression of the exogenous SPINK polypeptide).
  • expression of the SPINK polypeptide enhances, increases, augments, and/or supplements the anti-inflammatory and/or anti-microbial protection of mucous epithelia in the subject.
  • expression of the SPINK polypeptide enhances, increases, augments, and/or supplements the integrity and/or protective barrier function of the skin of the subject.
  • expression of the SPINK polypeptide decreases, augments, and/or inhibits one or more of Kallikrein-5 (KLK5), Kallikrein-7 (KLK7), Kallikrein-14 (KLK14), Caspase-14 (CASP14) and/or trypsin in the subject (e.g., decreases, augments, and/or inhibits one or more activities of KLK5, KLK7, KLK14, CASP14, and/or trypsin).
  • the present disclosure relates to recombinant nucleic acids comprising any one or more of the polynucleotides described herein.
  • the recombinant nucleic acid is a vector (e.g., an expression vector, a display vector, etc.).
  • the vector is a DNA vector or an RNA vector.
  • vectors suitable to maintain, propagate, and/or express polynucleotides to produce one or more polypeptides in a subject may be used.
  • suitable vectors may include, for example, plasmids, cosmids, episomes, transposons, and viral vectors (e.g., adenoviral vectors, adeno-associated viral vectors, vaccinia viral vectors, Sindbis-viral vectors, measles vectors, herpes viral vectors, lentiviral vectors, retroviral vectors, etc.).
  • the vector is a herpes viral vector.
  • the vector is capable of autonomous replication in a host cell.
  • the vector is incapable of autonomous replication in a host cell.
  • the vector can integrate into a host DNA.
  • the vector cannot integrate into a host DNA (e.g., is episomal).
  • Methods of making vectors containing one or more polynucleotides of interest are well known to one of ordinary skill in the art, including, for example, by chemical synthesis or by artificial manipulation of isolated segments of nucleic acids (e.g., by genetic engineering techniques).
  • a recombinant nucleic acid of the present disclosure is a herpes simplex virus (HSV) amplicon.
  • HSV herpes simplex virus
  • Herpes virus amplicons including the structural features and methods of making the same, are generally known to one of ordinary skill in the art (see e.g., de Silva S. and Bowers W. “Herpes Virus Amplicon Vectors”. Viruses 2009, 1, 594-629).
  • the herpes simplex virus amplicon is an HSV-1 amplicon.
  • the herpes simplex virus amplicon is an HSV-1 hybrid amplicon.
  • HSV-1 hybrid amplicons may include, but are not limited to, HSV/AAV hybrid amplicons, HSV/EBV hybrid amplicons, HSV/EBV/RV hybrid amplicons, and/or HSV/Sleeping Beauty hybrid amplicons.
  • the amplicon is an HSV/AAV hybrid amplicon.
  • the amplicon is an HSV/Sleeping Beauty hybrid amplicon.
  • a recombinant nucleic acid of the present disclosure is a recombinant herpes virus genome.
  • the recombinant herpes virus genome may be a recombinant genome from any member of the Herpesviridae family of DNA viruses known in the art, including, for example, a recombinant herpes simplex virus genome, a recombinant varicella zoster virus genome, a recombinant human cytomegalovirus genome, a recombinant herpesvirus 6A genome, a recombinant herpesvirus 6B genome, a recombinant herpesvirus 7 genome, a recombinant Kaposi's sarcoma-associated herpesvirus genome, and any combinations or derivatives thereof.
  • the recombinant herpes virus genome comprises one or more (e.g., one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, etc.) inactivating mutations.
  • the one or more inactivating mutations are in one or more (e.g., one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, etc.) herpes virus genes.
  • the recombinant herpes virus genome is attenuated (e.g., as compared to a corresponding, wild-type herpes virus genome). In some embodiments, the recombinant herpes virus genome is replication competent. In some embodiments, the recombinant herpes virus genome is replication defective.
  • the recombinant nucleic acid is a recombinant herpes simplex virus (HSV) genome.
  • the recombinant herpes simplex virus genome is a recombinant type 1 herpes simplex virus (HSV-1) genome, a recombinant type 2 herpes simplex virus (HSV-2) genome, or any derivatives thereof.
  • the recombinant herpes simplex virus genome is a recombinant HSV-1 genome.
  • the recombinant HSV-1 genome may be from any HSV-1 strain known in the art, including, for example, strains 17, Ty25, R62, S25, Ku86, S23, R11, Ty148, Ku47, H166syn, 1319-2005, F-13, M-12, 90237, F-17, KOS, 3083-2008, F12g, L2, CD38, H193, M-15, India 2011, 0116209, F-11I, 66-207, 2762, 369-2007, 3355, Maclntyre, McKrae, 7862, 7-hse, HF10, 1394,2005, 270-2007, OD4, SC16, M-19, 4J1037, 5J1060, J1060, KOS79, 132-1988, 160-1982, H166, 2158-2007, RE, 78326, F18g, F11, 172-2010, H129, F, E4, CJ994, F14g, E03, E22, E
  • the recombinant HSV-1 genome is from the KOS strain. In some embodiments, the recombinant HSV-1 genome is not from the McKrae strain. In some embodiments, the recombinant herpes simplex virus genome is attenuated. In some embodiments, the recombinant herpes simplex virus genome is replication competent. In some embodiments, the recombinant herpes simplex virus genome is replication defective.
  • the recombinant herpes simplex virus genome comprises one or more (e.g., one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, etc.) inactivating mutations.
  • the one or more inactivating mutations are in one or more (e.g., one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, etc.) herpes simplex virus genes.
  • an “inactivating mutation” may refer to any mutation that results in a gene or regulon product (RNA or protein) having reduced, undetectable, or eliminated quantity and/or function (e.g., as compared to a corresponding sequence lacking the inactivating mutation).
  • inactivating mutations may include, but are not limited to, deletions, insertions, point mutations, and rearrangements in transcriptional control sequences (promoters, enhancers, insulators, etc.) and/or coding sequences of a given gene or regulon. Any suitable method of measuring the quantity of a gene or regulon product known in the art may be used, including, for example, qPCR, Northern blots, RNAseq, western blots, ELISAs, etc.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or all eight of the Infected Cell Protein (or Infected Cell Polypeptide) (ICP) 0, ICP4, ICP22, ICP27, ICP47, thymidine kinase (tk), Long Unique Region (UL) 41 and/or UL55 herpes simplex virus genes.
  • ICP Infected Cell Protein
  • ICP4 Infected Cell Polypeptide
  • ICP22 ICP27
  • ICP47 thymidine kinase
  • tk thymidine kinase
  • UL Long Unique Region
  • the recombinant herpes simplex virus genome does not comprise an inactivating mutation in the ICP34.5 (one or both copies) and/or ICP47 herpes simplex virus genes (e.g., to avoid production of an immune-stimulating virus). In some embodiments, the recombinant herpes simplex virus genome does not comprise an inactivating mutation in the ICP34.5 (one or both copies) herpes simplex virus gene. In some embodiments, the recombinant herpes simplex virus genome does not comprise an inactivating mutation in the ICP47 herpes simplex virus gene.
  • the recombinant herpes simplex virus genome does not comprise an inactivating mutation in the ICP34.5 (one or both copies) and ICP47 herpes simplex virus genes. In some embodiments, the recombinant herpes simplex virus genome is not oncolytic.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 gene (one or both copies). In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 gene (one or both copies), and further comprises an inactivating mutation in the ICP4 (one or both copies), ICP22, ICP27, ICP47, UL41, and/or UL55 genes. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 gene (one or both copies), and an inactivating mutation in the ICP4 gene (one or both copies).
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 gene (one or both copies), and an inactivating mutation in the ICP22 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 gene (one or both copies), and an inactivating mutation in the UL41 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 gene (one or both copies), an inactivating mutation in the ICP4 gene (one or both copies), and an inactivating mutation in the ICP22 gene.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 gene (one or both copies), an inactivating mutation in the ICP4 gene (one or both copies), and an inactivating mutation in the UL41 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 gene (one or both copies), an inactivating mutation in the ICP22 gene, and an inactivating mutation in the UL41 gene.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 gene (one or both copies), an inactivating mutation in the ICP4 gene (one or both copies), an inactivating mutation in the ICP22 gene, and an inactivating mutation in the UL41 gene.
  • the inactivating mutation is a deletion of the coding sequence of the ICP0 (one or both copies), ICP4 (one or both copies), ICP22, and/or UL41 genes.
  • the recombinant herpes simplex virus genome further comprises an inactivating mutation in the ICP27, ICP47, and/or UL55 genes.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP4 gene (one or both copies). In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP4 gene (one or both copies), and further comprises an inactivating mutation in the ICP0 (one or both copies), ICP22, ICP27, ICP47, UL41, and/or UL55 genes. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP4 gene (one or both copies), and an inactivating mutation in the ICP22 gene.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP4 gene (one or both copies), and an inactivating mutation in the UL41 gene.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP4 gene (one or both copies), an inactivating mutation in the ICP22 gene, and an inactivating mutation in the UL41 gene.
  • the inactivating mutation is a deletion of the coding sequence of the ICP4 (one or both copies), ICP22, and/or UL41 genes.
  • the recombinant herpes simplex virus genome further comprises an inactivating mutation in the ICP0 (one or both copies), ICP27, ICP47, and/or UL55 genes.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP22 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP22 gene, and further comprises an inactivating mutation in the ICP0 (one or both copies), ICP4 (one or both copies), ICP27, ICP47, UL41, and/or UL55 genes. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP22 gene, and an inactivating mutation UL41 gene. In some embodiments, the inactivating mutation is a deletion of the coding sequence of the ICP22 and/or UL41 genes. In some embodiments, the recombinant herpes simplex virus genome further comprises an inactivating mutation in the ICP0 (one or both copies), ICP4 (one or both copies), ICP27, ICP47, and/or UL55 genes.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP27 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP27 gene, and further comprises an inactivating mutation in the ICP0 (one or both copies), ICP4 (one or both copies), ICP22, ICP47, UL41, and/or UL55 genes. In some embodiments, the inactivating mutation is a deletion of the coding sequence of the ICP27 gene.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP47 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP47 gene, and further comprises an inactivating mutation in the ICP0 (one or both copies), ICP4 (one or both copies), ICP22, ICP27, UL41, and/or UL55 genes. In some embodiments, the inactivating mutation is a deletion of the coding sequence of the ICP47 gene.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the UL41 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the UL41 gene, and further comprises an inactivating mutation in the ICP0 (one or both copies), ICP4 (one or both copies), ICP22, ICP27, ICP47, and/or UL55 genes. In some embodiments, the inactivating mutation is a deletion of the coding sequence of the UL41 gene.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the UL55 gene. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the UL55 gene, and further comprises an inactivating mutation in the ICP0 (one or both copies), ICP4 (one or both copies), ICP22, ICP27, ICP47, and/or UL41 genes. In some embodiments, the inactivating mutation is a deletion of the coding sequence of the UL55 gene.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in (e.g., a deletion of) the internal repeat (Joint) region comprising the internal repeat long (IR L ) and internal repeat short (IR S ) regions.
  • inactivation (e.g., deletion) of the Joint region eliminates one copy each of the ICP4 and ICP0 genes.
  • inactivation (e.g., deletion) of the Joint region further inactivates (e.g., deletes) the promoter for the ICP22 and ICP47 genes.
  • inactivating e.g., deleting
  • the Joint region may contribute to the stability of the recombinant herpes simplex virus genome and/or allow for the recombinant herpes simplex virus genome to accommodate more and/or larger transgenes.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP4 (one or both copies), ICP22, and ICP27 genes. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP4 (one or both copies), ICP27, and UL55 genes. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP4 (one or both copies), ICP22, ICP27, ICP47, and UL55 genes.
  • the inactivating mutation in the ICP4 (one or both copies), ICP27, and/or UL55 genes is a deletion of the coding sequence of the ICP4 (one or both copies), ICP27, and/or UL55 genes.
  • the inactivating mutation in the ICP22 and ICP47 genes is a deletion in the promoter region of the ICP22 and ICP47 genes (e.g., the ICP22 and ICP47 coding sequences are intact but are not transcriptionally active).
  • the recombinant herpes simplex virus genome comprises a deletion in the coding sequence of the ICP4 (one or both copies), ICP27, and UL55 genes, and a deletion in the promoter region of the ICP22 and ICP47 genes. In some embodiments, the recombinant herpes simplex virus genome further comprises an inactivating mutation in the ICP0 (one or both copies) and/or UL41 genes.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 (one or both copies) and ICP4 (one or both copies) genes. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 (one or both copies), ICP4 (one or both copies), and ICP22 genes. In some embodiments, the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 (one or both copies), ICP4 (one or both copies), ICP22, and ICP27 genes.
  • the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP0 (one or both copies), ICP4 (one or both copies), ICP22, ICP27 and UL55 genes.
  • the inactivating mutation in the ICP0 (one or both copies), ICP4 (one or both copies), ICP22, ICP27 and/or UL55 genes comprises a deletion of the coding sequence of the ICP0 (one or both copies), ICP4 (one or both copies), ICP22, ICP27 and/or UL55 genes.
  • the recombinant herpes simplex virus genome further comprises an inactivating mutation in the ICP47 and/or the UL41 genes.
  • a recombinant herpes simplex virus genome comprises one or more polynucleotides of the present disclosure within one, two, three, four, five, six, seven or more viral gene loci.
  • suitable viral loci may include, without limitation, the ICP0 (one or both copies), ICP4 (one or both copies), ICP22, ICP27, ICP47, tk, UL41 and/or UL55 herpes simplex viral gene loci.
  • a recombinant herpes simplex virus genome comprises one or more polynucleotides of the present disclosure within one or both of the viral ICP4 gene loci (e.g., a recombinant virus comprising a polynucleotide encoding a SPINK polypeptide in one or both of the ICP4 loci).
  • a recombinant herpes simplex virus genome comprises one or more polynucleotides of the present disclosure within the viral ICP22 gene locus (e.g., a recombinant virus comprising a polynucleotide encoding a SPINK polypeptide in the ICP22 locus).
  • a recombinant herpes simplex virus genome comprises one or more polynucleotides of the present disclosure within the viral UL41 gene locus (e.g., a recombinant virus comprising a polynucleotide encoding a SPINK polypeptide in the UL41 locus).
  • a recombinant herpes simplex virus genome comprises one or more polynucleotides of the present disclosure within the viral ICP47 gene locus (e.g., a recombinant virus comprising a polynucleotide encoding a SPINK polypeptide in the ICP47 locus).
  • a recombinant herpes simplex virus genome comprises one or more polynucleotides of the present disclosure within one or both of the viral ICP4 gene loci, and one or more polynucleotides of the present disclosure within the viral ICP22 gene locus (e.g., a recombinant virus comprising a polynucleotide encoding a SPINK polypeptide in one or both of the ICP4 loci, and a polynucleotide encoding the same or a different SPINK polypeptide in the ICP22 locus).
  • a recombinant herpes simplex virus genome comprises one or more polynucleotides of the present disclosure within one or both of the viral ICP4 gene loci, and one or more polynucleotides of the present disclosure within the viral UL41 gene locus (e.g., a recombinant virus comprising a polynucleotide encoding a SPINK polypeptide in one or both of the ICP4 loci, and a polynucleotide encoding the same or a different SPINK polypeptide in the UL41 locus).
  • a recombinant herpes simplex virus genome comprises one or more polynucleotides of the present disclosure within the viral ICP22 gene locus, and one or more polynucleotides of the present disclosure within the viral UL41 gene locus (e.g., a recombinant virus comprising a polynucleotide encoding a SPINK polypeptide in the ICP22 locus, and a polynucleotide encoding the same or a different SPINK polypeptide in the UL41 locus).
  • a recombinant herpes simplex virus genome comprises one or more polynucleotides of the present disclosure within one or both of the viral ICP4 gene loci, one or more polynucleotides of the present disclosure within the viral ICP22 gene locus, and one or more polynucleotides of the present disclosure within the viral UL41 gene locus (e.g., a recombinant virus comprising a polynucleotide encoding a SPINK polypeptide in one or both of the ICP4 loci, a polynucleotide encoding the same or a different SPINK polypeptide in the ICP22 locus, and a polynucleotide encoding a SPINK polypeptide in the UL41 locus (which may be the same SPINK polypeptide encoded in the ICP4 and/or ICP22 loci or may be a different SPINK polypeptide than those encoded in the ICP4 and/or
  • the recombinant herpes virus genome (e.g., a recombinant herpes simplex virus genome) has been engineered to decrease or eliminate expression of one or more herpes virus genes (e.g., one or more toxic herpes virus genes), such as one or both copies of the HSV ICP0 gene, one or both copies of the HSV ICP4 gene, the HSV ICP22 gene, the HSV UL41 gene, the HSV ICP27 gene, etc.
  • one or more herpes virus genes e.g., one or more toxic herpes virus genes
  • the recombinant herpes virus genome (e.g., recombinant herpes simplex virus genome) has been engineered to reduce cytotoxicity of the recombinant genome (e.g., when introduced into a target cell) as compared to a corresponding wild-type herpes virus genome (e.g., a wild-type herpes simplex virus genome).
  • the target cell is a human cell.
  • the target cell is a cell of the epidermis and/or dermis (e.g., a cell of the human epidermis and/or dermis).
  • the target cell is a keratinocyte or fibroblast (e.g., a human keratinocyte or human fibroblast).
  • cytotoxicity e.g., in human keratinocytes and/or fibroblasts
  • the recombinant genome e.g., a recombinant herpes simplex virus genome
  • the recombinant genome is reduced by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% as compared to a corresponding wild-type herpes virus genome (e.g., measuring the relative cytotoxicity of a recombinant ⁇ ICP4 (
  • a wild-type herpes simplex virus genome in human keratinocytes or fibroblasts primary cells or cell lines
  • a wild-type herpes simplex virus genome in human keratinocytes or fibroblasts primary cells or cell lines
  • cytotoxicity (e.g., in human keratinocytes and/or fibroblasts) of the recombinant genome is reduced by at least about 1.5-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 50-fold, at least about 75-fold, at least about 100-fold, at least about 250-fold, at least about 500-fold, at least about 750-fold, at least about 1000-fold, or more as compared to a corresponding wild-type herpes virus genome (e.g., measuring the relative cytotoxicity of a recombinant ⁇ ICP4 (one or both copies) herpes simplex virus genome v
  • a wild-type herpes simplex virus genome in human keratinocytes or fibroblasts primary cells or cell lines
  • a wild-type herpes simplex virus genome in human keratinocytes or fibroblasts primary cells or cell lines
  • cytotoxicity Methods of measuring cytotoxicity are known to one of ordinary skill in the art, including, for example, through the use of vital dyes (formazan dyes), protease biomarkers, an MTT assay (or an assay using related tetrazolium salts such as XTT, MTS, water-soluble tetrazolium salts, etc.), measuring ATP content, etc.
  • vital dyes formazan dyes
  • protease biomarkers an MTT assay (or an assay using related tetrazolium salts such as XTT, MTS, water-soluble tetrazolium salts, etc.), measuring ATP content, etc.
  • the recombinant herpes virus genome (e.g., a recombinant herpes simplex virus genome) has been engineered to reduce its impact on host cell proliferation after exposure of a target cell to the recombinant genome, as compared to a corresponding wild-type herpes virus genome (e.g., a wild-type herpes simplex virus genome).
  • the target cell is a human cell.
  • the target cell is a cell of the epidermis and/or dermis (e.g., a cell of the human epidermis and/or dermis).
  • the target cell is a keratinocyte or fibroblast (e.g., a human keratinocyte or human fibroblast).
  • host cell proliferation e.g., of human keratinocytes and/or fibroblasts
  • host cell proliferation is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% faster as compared to host cell proliferation after exposure to a corresponding wild-type herpes virus genome (e.g., measuring the relative cellular proliferation after exposure to a recombinant ⁇ ICP4 (one or both copies) herpes simplex virus genome
  • host cell proliferation (e.g., of human keratinocytes and/or fibroblasts) after exposure to the recombinant genome is at least about 1.5-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 50-fold, at least about 75-fold, at least about 100-fold, at least about 250-fold, at least about 500-fold, at least about 750-fold, or at least about 1000-fold faster as compared to host cell proliferation after exposure to a corresponding wild-type herpes virus genome (e.g., measuring the relative cellular proliferation after exposure to a recombinant ⁇ ICP4 (one or both copies) herpes simplex virus genome vs.
  • ⁇ ICP4 one or both copies
  • cellular proliferation after exposure to a wild-type herpes simplex virus genome in human keratinocytes or fibroblasts primary cells or cell lines
  • Methods of measuring cellular proliferation are known to one of ordinary skill in the art, including, for example, through the use of a Ki67 cell proliferation assay, a BrdU cell proliferation assay, etc.
  • a vector may include one or more polynucleotides of the present disclosure in a form suitable for expression of the polynucleotide in a host cell.
  • Vectors may include one or more regulatory sequences operatively linked to the polynucleotide to be expressed (e.g., as described above).
  • a recombinant nucleic acid (e.g., a recombinant herpes virus genome, such as a recombinant herpes simplex virus genome) of the present disclosure comprises one or more of the polynucleotides described herein inserted in any orientation in the recombinant nucleic acid. If the recombinant nucleic acid comprises two or more polynucleotides described herein (e.g., two or more, three or more, etc.), the polynucleotides may be inserted in the same orientation or opposite orientations to one another.
  • incorporating two polynucleotides e.g., two transgenes
  • a recombinant nucleic acid e.g., a vector
  • an antisense orientation may help to avoid read-through and ensure proper expression of each polynucleotide.
  • the present disclosure relates to one or more heterologous polynucleotides (e.g., a bacterial artificial chromosome (BAC)) comprising any of the recombinant nucleic acids described herein.
  • heterologous polynucleotides e.g., a bacterial artificial chromosome (BAC)
  • BAC bacterial artificial chromosome
  • viruses comprising any of the polynucleotides and/or recombinant nucleic acids described herein.
  • the virus is capable of infecting one or more target cells of a subject (e.g., a human).
  • the virus is suitable for delivering the polynucleotides and/or recombinant nucleic acids into one or more target cells of a subject (e.g., a human).
  • the present disclosure relates to one or more viral particles comprising any of the polynucleotides and/or recombinant nucleic acids described herein.
  • the one or more target cells are one or more human cells.
  • the one or more target cells are one or more cells with a SPINK deficiency (e.g., one or more cells comprising a loss-of-function mutation in, or a pathogenic variant of, a native SPINK gene, such as a SPINK5 gene).
  • the one or more target cells are one or more cells of the skin (e.g., one or more cells of the epidermis, dermis, and/or subcutis).
  • the one or more target cells are cells of the epidermis and/or dermis (e.g., cells of the human epidermis and/or dermis).
  • the one or more target cells are selected from keratinocytes, melanocytes, Langerhans cells, Merkel cells, mast cells, fibroblasts, and/or adipocytes. In some embodiments, the one or more target cells are keratinocytes. In some embodiments, the one or more target cells reside in the stratum corneum, stratum granulosum, stratum spinulosum, stratum basale, and/or basement membrane. In some embodiments, the one or more target cells are one or more epidermal cells. In some embodiments, the one or more target cells are one or more dermal cells.
  • any suitable virus known in the art may be used, including, for example, adenovirus, adeno-associated virus, retrovirus, lentivirus, sendai virus, papillomavirus, herpes virus (e.g., a herpes simplex virus), vaccinia virus, and/or any hybrid or derivative viruses thereof.
  • the virus is attenuated.
  • the virus is replication defective.
  • the virus is replication competent.
  • the virus has been modified to alter its tissue tropism relative to the tissue tropism of a corresponding unmodified, wild-type virus.
  • the virus has reduced cytotoxicity as compared to a corresponding wild-type virus.
  • the virus is a member of the Herpesviridae family of DNA viruses, including, for example, a herpes simplex virus, a varicella zoster virus, a human cytomegalovirus, a herpesvirus 6A, a herpesvirus 6B, a herpesvirus 7, and a Kaposi's sarcoma-associated herpesvirus, etc.
  • the herpes virus is attenuated.
  • the herpes virus is replication defective.
  • the herpes virus is replication competent.
  • the herpes virus has reduced cytotoxicity as compared to a corresponding wild-type herpes virus.
  • the herpes virus is not oncolytic.
  • the herpes virus is a herpes simplex virus.
  • Herpes simplex viruses comprising recombinant nucleic acids may be produced by a process disclosed, for example, in WO2015/009952 and/or WO2017/176336.
  • the herpes simplex virus is attenuated.
  • the herpes simplex virus is replication defective.
  • the herpes simplex virus is replication competent.
  • the herpes simplex virus is an HSV-1 virus, an HSV-2, or any derivatives thereof.
  • the herpes simplex virus is an HSV-1 virus.
  • the HSV-1 is attenuated.
  • the HSV-1 is replication defective. In some embodiments, the HSV-1 is replication competent. In some embodiments, the herpes simplex virus (e.g., the HSV-1) has reduced cytotoxicity as compared to a corresponding wild-type herpes simplex virus (e.g., a wild-type HSV-1). In some embodiments, the herpes simplex virus (e.g., the HSV-1) is not oncolytic.
  • the herpes simplex virus has been modified to alter its tissue tropism relative to the tissue tropism of an unmodified, wild-type herpes simplex virus.
  • the herpes simplex virus comprises a modified envelope.
  • the modified envelope comprises one or more (e.g., one or more, two or more, three or more, four or more, etc.) mutant herpes simplex virus glycoproteins. Examples of herpes simplex virus glycoproteins may include, but are not limited to, the glycoproteins gB, gC, gD, gH, and gL.
  • the modified envelope alters the herpes simplex virus tissue tropism relative to a wild-type herpes simplex virus.
  • the transduction efficiency (in vitro and/or in vivo) of a virus of the present disclosure e.g., a herpes virus such as a herpes simplex virus
  • a virus of the present disclosure e.g., a herpes virus such as a herpes simplex virus
  • target cells e.g., one or more human keratinocytes and/or fibroblasts
  • the transduction efficiency of the virus for one or more target cells may be at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, at least about 99.5%, or more.
  • the virus is a herpes simplex virus and the transduction efficiency of the virus for one or more target cells (e.g., one or more human keratinocytes and/or fibroblasts) is about 85% to about 100%.
  • the virus is a herpes simplex virus and the transduction efficiency of the virus for one or more target cells (e.g., one or more human keratinocytes and/or fibroblasts) is at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100%.
  • target cells e.g., one or more human keratinocytes and/or fibroblasts
  • Methods of measuring viral transduction efficiency in vitro or in vivo are well known to one of ordinary skill in the art, including, for example, qPCR analysis, deep sequencing, western blotting, fluorometric analysis (such as fluorescent in situ hybridization (FISH), fluorescent reporter gene expression, immunofluorescence, FACS), etc.
  • fluorometric analysis such as fluorescent in situ hybridization (FISH), fluorescent reporter gene expression, immunofluorescence, FACS
  • compositions and formulations comprising any of the recombinant nucleic acids (e.g., recombinant herpes virus genomes) and/or viruses (e.g., herpes viruses comprising the recombinant genomes) described herein (such as a herpes simplex virus comprising a recombinant herpes simplex virus genome), and a pharmaceutically acceptable excipient or carrier.
  • recombinant nucleic acids e.g., recombinant herpes virus genomes
  • viruses e.g., herpes viruses comprising the recombinant genomes described herein (such as a herpes simplex virus comprising a recombinant herpes simplex virus genome)
  • a pharmaceutically acceptable excipient or carrier e.g., a pharmaceutically acceptable excipient or carrier.
  • the pharmaceutical composition or formulation comprises any one or more of the viruses (e.g., herpes viruses) described herein. In some embodiments, the pharmaceutical composition or formulation comprises from about 10 4 to about 10 12 plaque forming units (PFU)/mL of the virus.
  • viruses e.g., herpes viruses
  • PFU plaque forming units
  • the pharmaceutical composition or formulation may comprise from about 10 4 to about 10 12 , about 10 5 to about 10 12 , about 10 6 to about 10 12 , about 10 11 to about 10 12 , about 10 8 to about 10 12 , about 10 9 to about 10 12 , about 10 10 to about 10 12 , about 10 11 to about 10 12 , about 10 4 to about 10 11 , about 10 5 to about 10 11 , about 10 6 to about 10 11 , about 10 7 to about 10 11 , about 10 8 to about 10 11 , about 10 9 to about 10 11 , about 10 10 to about 10 11 , about 10 4 to about 10 10 about 10 5 to about 10 10 about 10 6 to about 10 10 , about 10 7 to about 10 10 about 10 about 10 about 10 8 to about 10 10 about 10 9 to about 10 10 about 10 4 to about 10 9 about 10 5 to about 10 9 , about 10 6 to about 10 9 , about 10 7 to about 10 9 , about 10 8 to about 10 9 , about 10 4 to about 10 8 , about 10 5 to about 10 8 , about 10
  • the pharmaceutical composition or formulation comprises about 10 4 , about 10 5 , about 10 6 , about 10 7 , about 10 8 , about 10 9 , about 10 10 , about 10 11 , or about 10 12 PFU/mL of the virus.
  • compositions and formulations can be prepared by mixing the active ingredient(s) (such as a recombinant nucleic acid and/or a virus) having the desired degree of purity with one or more pharmaceutically acceptable carriers or excipients.
  • Pharmaceutically acceptable carriers or excipients are generally nontoxic to recipients at the dosages and concentrations employed, and may include, but are not limited to: buffers (such as phosphate, citrate, acetate, and other organic acids); antioxidants (such as ascorbic acid and methionine); preservatives (such as octadecyldimethylbenzyl ammonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl or benzyl alcohol, alkyl parabens, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol); amino acids (such as glycine, glutamine, asparagine, histidine, arginine
  • glycerol hydrophilic polymers (such as polyvinylpyrrolidone); monosaccharides, disaccharides, and other carbohydrates (including glucose, mannose, or dextrins); chelating agents (such as EDTA); sugars (such as sucrose, mannitol, trehalose, or sorbitol); salt-forming counter-ions (such as sodium); metal complexes (such as Zn-protein complexes); and/or non-ionic surfactants (such as polyethylene glycol (PEG)).
  • hydrophilic polymers such as polyvinylpyrrolidone
  • monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins
  • chelating agents such as EDTA
  • sugars such as sucrose, mannitol, trehalose, or sorbitol
  • salt-forming counter-ions such as sodium
  • metal complexes such as Zn-protein complexes
  • non-ionic surfactants
  • the pharmaceutical composition or formulation comprises one or more lipid (e.g., cationic lipid) carriers.
  • the pharmaceutical composition or formulation comprises one or more nanoparticle carriers.
  • Nanoparticles are submicron (less than about 1000 nm) sized drug delivery vehicles that can carry encapsulated drugs (such as synthetic small molecules, proteins, peptides, cells, viruses, and nucleic acid-based biotherapeutics) for rapid or controlled release.
  • encapsulated drugs such as synthetic small molecules, proteins, peptides, cells, viruses, and nucleic acid-based biotherapeutics
  • a variety of molecules e.g., proteins, peptides, recombinant nucleic acids, etc.
  • a molecule “encapsulated” in a nanoparticle may refer to a molecule (such as a virus) that is contained within the nanoparticle or attached to and/or associated with the surface of the nanoparticle, or any combination thereof.
  • Nanoparticles for use in the compositions or formulations described herein may be any type of biocompatible nanoparticle known in the art, including, for example, nanoparticles comprising poly(lactic acid), poly(glycolic acid), PLGA, PLA, PGA, and any combinations thereof (see e.g., Vauthier et al. Adv Drug Del Rev. (2003) 55: 519-48; US2007/0148074; US2007/0092575; US2006/0246139; U.S. Pat. Nos. 5,753,234; 7,081,483; and WO2006/052285).
  • the pharmaceutically acceptable carrier or excipient may be adapted for or suitable for any administration route known in the art, including, for example, intravenous, intramuscular, subcutaneous, cutaneous, oral, nasal, intratracheal, sublingual, buccal, topical, transdermal, intradermal, intraperitoneal, intraorbital, intravitreal, subretinal, transmucosal, intraarticular, by implantation, by inhalation, intrathecal, intraventricular, and/or intranasal administration.
  • any administration route known in the art including, for example, intravenous, intramuscular, subcutaneous, cutaneous, oral, nasal, intratracheal, sublingual, buccal, topical, transdermal, intradermal, intraperitoneal, intraorbital, intravitreal, subretinal, transmucosal, intraarticular, by implantation, by inhalation, intrathecal, intraventricular, and/or intranasal administration.
  • the pharmaceutical composition or formulation is adapted for or suitable for any administration route known in the art, including, for example, intravenous, intramuscular, subcutaneous, cutaneous, oral, nasal, intratracheal, sublingual, buccal, topical, transdermal, intradermal, intraperitoneal, intraorbital, intravitreal, subretinal, transmucosal, intraarticular, by implantation, by inhalation, intrathecal, intraventricular, and/or intranasal administration.
  • the pharmaceutically acceptable carrier or excipient is adapted for or suitable for topical, transdermal, subcutaneous, intradermal, and/or transmucosal administration.
  • the pharmaceutical composition or formulation is adapted for or suitable for topical, transdermal, subcutaneous, intradermal, and/or transmucosal administration.
  • the pharmaceutically acceptable carrier or excipient is adapted for or suitable for topical, transdermal, and/or intradermal administration.
  • the pharmaceutical composition or formulation is adapted for or suitable for topical, transdermal, and/or intradermal administration.
  • the pharmaceutically acceptable carrier or excipient is adapted for or suitable for topical administration.
  • the pharmaceutical composition or formulation is adapted for or suitable for topical administration.
  • Examples of carriers or excipients adapted for or suitable for use in pharmaceutical compositions or formulations of the present disclosure may include, but are not limited to, ointments, oils, pastes, creams, aerosols, suspensions, emulsions, fatty ointments, gels (e.g., methylcellulose gels, such as carboxy methylcellulose, hydroxypropyl methylcellulose, etc.), powders, liquids, lotions, solutions, sprays, patches (e.g., transdermal patches or microneedle patches), adhesive strips, a microneedle or microneedle arrays, and inhalants.
  • ointments oils, pastes, creams, aerosols, suspensions, emulsions, fatty ointments, gels (e.g., methylcellulose gels, such as carboxy methylcellulose, hydroxypropyl methylcellulose, etc.), powders, liquids, lotions, solutions, sprays, patches (e.g., transdermal patches or
  • the carrier or excipient comprises one or more (e.g., one or more, two or more, three or more, four or more, five or more, etc.) of an ointment, oil, paste, cream, aerosol, suspension, emulsion, fatty ointment, gel, powder, liquid, lotion, solution, spray, patch, adhesive strip, and an inhalant.
  • the carrier comprises a patch (e.g. a patch that adheres to the skin), such as a transdermal patch or microneedle patch.
  • the carrier comprises a microneedle or microneedle array.
  • microneedle arrays suitable for composition delivery are generally known in the art (see e.g., Kim Y. et al. “Microneedles for drug and vaccine delivery”. Advanced Drug Delivery Reviews 2012, 64 (14): 1547-68).
  • the pharmaceutical composition or formulation further comprises one or more additional components.
  • additional components may include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); wetting agents (e.g., sodium lauryl sulphate, etc.); salt solutions; alcohols; polyethylene glycols; gelatin;
  • the pharmaceutical composition or formulation comprises a methylcellulose gel, such as a carboxy methylcellulose gel, a hydroxypropyl methylcellulose gel, etc. (e.g., at about 0.5%, at about 1%, at about 1.5%, at about 2%, at about 2.5%, at about 3%, at about 3.5%, at about 4%, at about 4.5%, at about 5%, at about 5.5%, at about 6%, at about 6.5%, at about 7%, at about 7.5%, at about 8%, at about 8.5%, at about 9%, at about 9.5%, at about 10%, at about 10.5%, at about 11%, at about 11.5%, at about 12%, etc.).
  • the pharmaceutical composition or formulation comprises a phosphate buffer.
  • the pharmaceutical composition or formulation comprises glycerol (e.g., at about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, etc.).
  • the pharmaceutical composition or formulation comprises a methylcellulose gel (a carboxy methylcellulose gel, a hydroxypropyl methylcellulose gel, etc.), a phosphate buffer, and/or glycerol.
  • compositions and formulations e.g., pharmaceutical compositions and formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
  • any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations described herein may be used to deliver one or more polynucleotides encoding a SPINK polypeptide into one or more cells of a subject (e.g., one or more SPINK-deficient cells, one or more cells harboring a SPINK gene mutation, etc.).
  • any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations may be used in a therapy.
  • any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations described herein may be used in the treatment of a disease or condition that would benefit from the expression of a SPINK polypeptide (e.g., a disease associated with a SPINK deficiency and/or a disease associated with a SPINK gene mutation).
  • a SPINK polypeptide e.g., a disease associated with a SPINK deficiency and/or a disease associated with a SPINK gene mutation.
  • any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations described herein may be used for providing prophylactic, palliative, or therapeutic relief to one or more signs or symptoms of Netherton Syndrome (e.g., via delivery of a SPINK5 polypeptide), atopic dermatitis (e.g., via delivery of a SPINK5 polypeptide), hereditary pancreatitis (PCTT) (e.g., via delivery of a SPINK1 polypeptide), tropical calcific pancreatitis (e.g., via delivery of a SPINK1 polypeptide), and/or spermatogenic failure 29 (SPGF29) (e.g., via delivery of a SPINK2 polypeptide).
  • Netherton Syndrome e.g., via delivery of a SPINK5 polypeptide
  • atopic dermatitis e.g., via delivery of a SPINK5 polypeptide
  • PCTT hereditary pancrea
  • any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations described herein may be used to treat Netherton Syndrome (e.g., via delivery of a human SPINK5 polypeptide). In some embodiments, any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations described herein may be used to treat atopic dermatitis (e.g., via delivery of a human SPINK5 polypeptide).
  • any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations described herein may be used in the preparation or manufacture of a medicament.
  • any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations described herein may be used in the preparation or manufacture of a medicament useful for delivering one or more polynucleotides encoding a SPINK polypeptide into one or more cells of a subject (e.g., one or more SPINK-deficient cells, one or more cells harboring a SPINK gene mutation, etc.).
  • any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations described herein may be used in the preparation or manufacture of a medicament useful for the treatment of a disease or condition that would benefit from the expression of a SPINK polypeptide (e.g., a disease associated with a SPINK deficiency and/or a disease associated with a SPINK gene mutation).
  • a SPINK polypeptide e.g., a disease associated with a SPINK deficiency and/or a disease associated with a SPINK gene mutation.
  • any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations described herein may be used in the preparation or manufacture of a medicament useful for the treatment of Netherton Syndrome (e.g., via delivery of a SPINK5 polypeptide), atopic dermatitis (e.g., via delivery of a SPINK5 polypeptide), hereditary pancreatitis (PCTT) (e.g., via delivery of a SPINK1 polypeptide), tropical calcific pancreatitis (e.g., via delivery of a SPINK1 polypeptide), and/or spermatogenic failure 29 (SPGF29) (e.g., via delivery of a SPINK2 polypeptide).
  • Netherton Syndrome e.g., via delivery of a SPINK5 polypeptide
  • atopic dermatitis e.g., via delivery of a SPINK5 polypeptide
  • PCTT hereditary pancreatitis
  • any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations described herein may be used in the preparation or manufacture of a medicament useful for the treatment of Netherton Syndrome (e.g., via delivery of a human SPINK5 polypeptide).
  • any of the recombinant nucleic acids, viruses, and/or pharmaceutical compositions or formulations described herein may be used in the preparation or manufacture of a medicament useful for the treatment of atopic dermatitis (e.g., via delivery of a human SPINK5 polypeptide).
  • Certain aspects of the present disclosure relate to enhancing, increasing, augmenting, and/or supplementing the levels of a SPINK polypeptide in one or more cells of a subject comprising administering to the subject an effective amount of any of the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations described herein.
  • the SPINK polypeptide is a human SPINK polypeptide.
  • the SPINK polypeptide is a SPINK5 polypeptide.
  • the SPINK5 polypeptide is a human SPINK5 polypeptide.
  • the subject is a human.
  • the subject's genome comprises a mutation (e.g., a loss-of-function mutation, a pathogenic variant) in an endogenous SPINK gene (such as an endogenous SPINK5 gene).
  • a mutation e.g., a loss-of-function mutation, a pathogenic variant
  • the subject suffers from Netherton Syndrome.
  • the subject suffers from atopic dermatitis.
  • administration of the recombinant nucleic acid, virus, medicament, and/or pharmaceutical composition or formulation to the subject increases SPINK (e.g., SPINK5) levels (transcript or protein levels) by at least about 2-fold in one or more contacted or treated cells of the subject, as compared to the endogenous levels of the SPINK in one or more corresponding untreated cells of the subject.
  • SPINK e.g., SPINK5
  • administration of the recombinant nucleic acid, virus, medicament, and/or pharmaceutical composition or formulation may increase SPINK (e.g., SPINK5) levels (transcript or protein levels) by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 50-fold, at least about 75-fold, at least about 100-fold, at least about 250-fold, at least about 500-fold, at least about 750-fold, at least about 1000-fold, or more in one or more contacted or treated cells of the subject, as compared to the endogenous levels of the SPINK in one or more corresponding untreated cells of the subject.
  • SPINK e.g., SPINK5
  • SPINK5 levels transcript or protein levels
  • the one or more contacted or treated cells are one or more cells of the epidermis and/or dermis (e.g., a keratinocyte).
  • Methods of measuring transcript or protein levels from a sample are well known to one of ordinary skill in the art, including, for example, by qPCR, western blot, mass spectrometry, etc.
  • administering to an individual an effective amount of any of the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulation described herein enhances, increases, augments, and/or supplements the integrity and/or protective barrier function of the skin of the subject.
  • administering to an individual an effective amount of any of the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations described herein decreases, augments, and/or inhibits one or more of Kallikrein-5 (KLK5), Kallikrein-7 (KLK7), Kallikrein-14 (KLK14), Caspase-14 (CASP14) and trypsin in the subject (e.g., decreases, augments, and/or inhibits one or more activities (e.g., proteolytic activities) of KLK5, KLK7, KLK14, CASP14, and/or trypsin).
  • KLK5 Kallikrein-5
  • KLK7 Kallikrein-7
  • KLK14 Kallikrein-14
  • CAP14 Caspase-14
  • trypsin e.g., decreases, augments, and/or inhibits one or more activities (e.g., proteolytic activities) of KLK5, KLK7, KLK14, CASP14, and/
  • aspects of the present disclosure relate to enhancing, increasing, augmenting, and/or supplementing anti-inflammatory and/or anti-microbial protection of mucous epithelia in a subject in need thereof comprising administering to the subject an effective amount of any of the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations described herein.
  • administration of the recombinant nucleic acid, virus, medicament, and/or pharmaceutical composition reduces the susceptibility to skin infections of the subject.
  • aspects of the present disclosure relate to repressing or inhibiting desquamation in a subject in need thereof comprising administering to the subject an effective amount of any of the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations described herein.
  • a skin barrier defect in a subject in need thereof comprising administering to the subject an effective amount of any of the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations described herein.
  • the skin barrier defect is transepidermal water loss (TEWL), also called transepithelial water loss.
  • the methods of the present disclosure reduce transepidermal water loss in a subject in need thereof.
  • Methods of measuring skin barrier function, including TEWL are well known to one of ordinary skill in the art, including, for example, by any of the methods described by Antonov et al. (Curr Probl Dermatol. 2016; 49:61-70).
  • aspects of the present disclosure relate to providing prophylactic, palliative, or therapeutic relief of one or more signs or symptoms of Netherton Syndrome in a subject in need thereof comprising administering to the subject an effective amount of any of the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations described herein.
  • the subject's genome comprises a mutation (e.g., a loss-of-function mutation, a pathogenic variant) in an endogenous SPINK5 gene.
  • the recombinant nucleic acid, virus, medicament, and/or pharmaceutical composition or formulation comprises one or more polynucleotides encoding a human SPINK5 polypeptide.
  • Signs and/or symptoms of Netherton Syndrome may include, but are not limited to defective keratinization, a defective skin barrier, chronic skin inflammation, universal pruritus (itch), severe dehydration, stunted growth, trichorrhexis invaginata and/or trichorrhexis nodosa (hair shaft defect, also known as bamboo hair), leaking fluid from the skin, development of ring-like lesions on the skin, eczema, increased susceptibility to infection (particularly of the skin, including recurrent skin infections with Staphylococcus ), increased susceptibility to allergy, development of scaly/reddish skin (similar to atopic dermatitis), development of ichthyosis linearis circumflexa and/or ichthyosiform erythroderma, altered immunoglobulin levels (typically high IgE and low to normal IgG immunoglobulins), immature natural killer cells (having reduced lytic function), and difficulty regulating body temperature.
  • aspects of the present disclosure relate to providing prophylactic, palliative, or therapeutic relief of one or more signs or symptoms of atopic dermatitis in a subject in need thereof comprising administering to the subject an effective amount of any of the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations described herein.
  • the subject's genome comprises a mutation (e.g., a loss-of-function mutation, a pathogenic variant) in an endogenous SPINK5 gene.
  • the recombinant nucleic acid, virus, medicament, and/or pharmaceutical composition or formulation comprises one or more polynucleotides encoding a human SPINK5 polypeptide.
  • Signs and symptoms of atopic dermatitis may include, without limitation: dry skin; itching, which may be severe, especially at night; red to brownish-gray patches, especially on the hands, feet, ankles, wrists, neck, upper chest, eyelids, inside the bend of the elbows and knees, and in infants, the face and scalp; small, raised bumps on the skin which may be weeping; skin infections; eyelid dermatitis; cataracts; increased IgE levels; thickened, cracked, or scaly skin; and raw, sensitive, swollen skin from scratching.
  • nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations described herein may be administered by any suitable method or route known in the art, including, without limitation, orally, sublingually, buccally, topically, rectally, via inhalation, transdermally, subcutaneously, intradermally, intravenously, intraarterially, intramuscularly, intracardially, intraosseously, intraperitoneally, transmucosally, vaginally, intravitreally, intraorbitally, subretinally, intraarticularly, peri-articularly, locally, epicutaneously, or any combinations thereof.
  • the present disclosure thus encompasses methods of delivering any of the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations described herein to an individual (e.g., an individual having, or at risk of developing, Netherton Syndrome and/or atopic dermatitis).
  • the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations described herein are administered topically, transdermally, subcutaneously, intradermally, or transmucosally to the subject. In some embodiments, the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations are administered topically, transdermally, or intradermally to the subject. In some embodiments, the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations are administered topically or intradermally to the subject. In some embodiments, the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations are administered topically to the subject.
  • the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations are administered once to the subject. In some embodiments, the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations are administered at least twice (e.g., at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 10 times, etc.) to the subject.
  • At least about 1 hour e.g., at least about 1 hour, at least about 6 hours, at least about 12 hours, at least about 18 hours, at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 15 days, at least about 20 days, at least about 30 days, at least about 40 days, at least about 50 days, at least about 60 days, at least about 70 days, at least about 80 days, at least about 90 days, at least about 100 days, at least about 120 days, etc.) pass between administrations (e.g., between the first and second administrations, between the second and third administrations, etc.).
  • administrations e.g., between the first and second administrations, between the second and third administrations, etc.
  • the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations are administered one, two, three, four, five or more times per day to the subject. In some embodiments, the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations are administered to one or more affected (e.g., one or more regions of the skin displaying one or more signs or symptoms of Netherton Syndrome and/or atopic dermatitis) and/or unaffected areas of the subject.
  • affected e.g., one or more regions of the skin displaying one or more signs or symptoms of Netherton Syndrome and/or atopic dermatitis
  • one or more portions of the skin of the subject is abraded or made more permeable prior to treatment.
  • Any suitable method of abrading the skin or increasing skin permeability known in the art may be used, including, for example, use of a dermal roller, repeated use of adhesive strips to remove layers of skin cells (tape stripping), scraping with a scalpel or blade, use of sandpaper, use of chemical permeation enhancers or electrical energy, use of sonic or ultrasonic energy, use of light (e.g., laser) energy, use of micron-sized needles or blades with a length suitable to pierce but not completely pass through the epidermis, etc.
  • light e.g., laser
  • prokaryotic cells comprising any of the recombinant nucleic acids described herein.
  • Any suitable host cell known in the art may be used, including, for example: prokaryotic cells including eubacteria, such as Gram-negative or Gram-positive organisms, for example Enterobacteriaceae such as Escherichia (e.g., E. coli ), Enterobacter, Erminia, Klebsiella, Proteus, Salmonella (e.g., S. typhimurium ), Serratia (e.g., S. marcescans ), and Shigella , as well as Bacilli such as B. subtilis and B.
  • eubacteria such as Gram-negative or Gram-positive organisms
  • Enterobacteriaceae such as Escherichia (e.g., E. coli )
  • Enterobacter Erminia
  • Klebsiella Proteus
  • Salmonella e.g., S. typhimurium
  • licheniformis alian cell
  • fungal cells e.g., S. cerevisiae
  • insect cells e.g., S2 cells, etc.
  • mammalian cells including monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651), human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture), baby hamster kidney cells (BHK, ATCC CCL 10), mouse Sertoli cells (TM4), monkey kidney cells (CV1 ATCC CCL 70), African green monkey kidney cells (VERO-76, ATCC CRL-1587), human cervical carcinoma cells (HELA, ATCC CCL 2), canine kidney cells (MDCK, ATCC CCL 34), buffalo rat liver cells (BRL 3A, ATCC CRL 1442), human lung cells (W138, ATCC CCL 75), human liver cells (Hep G2, HB 8065), mouse mammary tumor (MMT 060562, ATCC CCL51), TRI cells, MRC 5 cells, FS4 cells,
  • the host cell is a human or non-human primate cell.
  • the host cells are cells from a cell line. Examples of suitable host cells or cell lines may include, but are not limited to, 293, HeLa, SH-Sy5y, Hep G2, CACO-2, A549, L929, 3T3, K562, CHO-K1, MDCK, HUVEC, Vero, N20, COS-7, PSN1, VCaP, CHO cells, and the like.
  • the recombinant nucleic acid is a herpes simplex viral vector. In some embodiments, the recombinant nucleic acid is a herpes simplex virus amplicon. In some embodiments, the recombinant nucleic acid is an HSV-1 amplicon or HSV-1 hybrid amplicon. In some embodiments, a host cell comprising a helper virus is contacted with an HSV-1 amplicon or HSV-1 hybrid amplicon described herein, resulting in the production of a virus comprising one or more recombinant nucleic acids described herein. In some embodiments, the virus is collected from the supernatant of the contacted host cell. Methods of generating virus by contacting host cells comprising a helper virus with an HSV-1 amplicon or HSV-1 hybrid amplicon are known in the art.
  • the host cell is a complementing host cell.
  • the complementing host cell expresses one or more genes that are inactivated in any of the viral vectors described herein.
  • the complementing host cell is contacted with a recombinant herpes virus genome (e.g., a recombinant herpes simplex virus genome) described herein.
  • contacting a complementing host cell with a recombinant herpes virus genome results in the production of a herpes virus comprising one or more recombinant nucleic acids described herein.
  • the virus is collected from the supernatant of the contacted host cell. Methods of generating virus by contacting complementing host cells with a recombinant herpes simplex virus are generally described in WO2015/009952 and/or WO2017/176336.
  • the article of manufacture or kit comprises a package insert comprising instructions for administering the recombinant nucleic acid, virus, medicament, and/or pharmaceutical composition or formulation to treat a SPINK deficiency (e.g., in a subject harboring a SPINK gene mutation) and/or to provide prophylactic, palliative, or therapeutic relief of one or more signs or symptoms of a disease associated with a SPINK deficiency (such as Netherton Syndrome and/or atopic dermatitis).
  • a SPINK deficiency e.g., in a subject harboring a SPINK gene mutation
  • Suitable containers for the recombinant nucleic acids, viruses, medicaments, and/or pharmaceutical compositions or formulations may include, for example, bottles, vials, bags, tubes, and syringes.
  • the container may be formed from a variety of materials such as glass, plastic (such as polyvinyl chloride or polyolefin), or metal alloy (such as stainless steel or hastelloy).
  • the container comprises a label on, or associated with the container, wherein the label indicates directions for use.
  • the article of manufacture or kit may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, package inserts, and the like.
  • Embodiment 1 a recombinant herpes virus genome comprising one or more polynucleotides encoding a Serine Protease Inhibitor Kazal-type (SPINK) polypeptide.
  • SPINK Serine Protease Inhibitor Kazal-type
  • Embodiment 2 the recombinant herpes virus genome of embodiment 1, wherein the recombinant herpes virus genome is replication competent.
  • Embodiment 3 the recombinant herpes virus genome of embodiment 1, wherein the recombinant herpes virus genome is replication defective.
  • Embodiment 4 the recombinant herpes virus genome of any one of embodiments 1-3, wherein the recombinant herpes virus genome comprises the one or more polynucleotides encoding the SPINK polypeptide within one or more viral gene loci.
  • Embodiment 5 the recombinant herpes virus genome of any one of embodiments 1-4, wherein the recombinant herpes virus genome is selected from a recombinant herpes simplex virus genome, a recombinant varicella zoster virus genome, a recombinant human cytomegalovirus genome, a recombinant herpesvirus 6A genome, a recombinant herpesvirus 6B genome, a recombinant herpesvirus 7 genome, a recombinant Kaposi's sarcoma-associated herpesvirus genome, and any derivatives thereof.
  • the recombinant herpes virus genome is selected from a recombinant herpes simplex virus genome, a recombinant varicella zoster virus genome, a recombinant human cytomegalovirus genome, a recombinant herpesvirus 6A genome, a recombinant herpesvirus 6
  • Embodiment 6 the recombinant herpes virus genome of any one of embodiments 1-5, wherein the recombinant herpes virus genome is a recombinant herpes simplex virus genome.
  • Embodiment 7 the recombinant herpes virus genome of embodiment 5 or embodiment 6, wherein the recombinant herpes simplex virus genome is a recombinant type 1 herpes simplex virus (HSV-1) genome, a recombinant type 2 herpes simplex virus (HSV-2) genome, or any derivatives thereof.
  • HSV-1 recombinant type 1 herpes simplex virus
  • HSV-2 recombinant type 2 herpes simplex virus
  • Embodiment 8 the recombinant herpes virus genome of any one of embodiments 1-7, wherein the SPINK polypeptide is a human SPINK polypeptide.
  • Embodiment 9 the recombinant herpes virus genome of any one of embodiments 1-7, wherein the SPINK polypeptide is a Serine Protease Inhibitor Kazal-type 5 (SPINK5) polypeptide.
  • SPINK5 Serine Protease Inhibitor Kazal-type 5
  • Embodiment 10 the recombinant herpes virus genome of any one of embodiments 1-9, wherein the SPINK polypeptide is a human SPINK5 polypeptide.
  • Embodiment 11 the recombinant herpes virus genome of embodiment 9 or embodiment 10, wherein the SPINK5 polypeptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence selected from SEQ ID NOS: 7-25.
  • Embodiment 12 the recombinant herpes virus genome of any one of embodiments 9-11, wherein the SPINK5 polypeptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence selected from SEQ ID NOS: 7-9.
  • Embodiment 13 the recombinant herpes virus genome of any one of embodiments 9-12, wherein the SPINK5 polypeptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7.
  • Embodiment 14 the recombinant herpes virus genome of any one of embodiments 5-13, wherein the recombinant herpes simplex virus genome comprises an inactivating mutation.
  • Embodiment 15 the recombinant herpes virus genome of embodiment 14, wherein the inactivating mutation is in a herpes simplex virus gene.
  • Embodiment 16 the recombinant herpes virus genome of embodiment 15, wherein the inactivating mutation is a deletion of the coding sequence of the herpes simplex virus gene.
  • Embodiment 17 the recombinant herpes virus genome of embodiment 15 or embodiment 16, wherein the herpes simplex virus gene is selected from Infected Cell Protein (ICP) 0, ICP4, ICP22, ICP27, ICP47, thymidine kinase (tk), Long Unique Region (UL) 41, and UL55.
  • ICP Infected Cell Protein
  • ICP4 ICP4, ICP22, ICP27, ICP47, thymidine kinase (tk), Long Unique Region (UL) 41, and UL55.
  • ICP Infected Cell Protein
  • tk thymidine kinase
  • UL Long Unique Region
  • Embodiment 18 the recombinant herpes virus genome of embodiment 17, wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in one or both copies of the ICP4 gene.
  • Embodiment 19 the recombinant herpes virus genome of embodiment 17 or embodiment 18, wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP22 gene.
  • Embodiment 20 the recombinant herpes virus genome of any one of embodiments 17-19, wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in the UL41 gene.
  • Embodiment 21 the recombinant herpes virus genome of any one of embodiments 17-20, wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in one or both copies of the ICP0 gene.
  • Embodiment 22 the recombinant herpes virus genome of any one of embodiments 17-21, wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in the ICP27 gene.
  • Embodiment 23 the recombinant herpes virus genome of any one of embodiments 5-22, wherein the recombinant herpes simplex virus genome comprises the one or more polynucleotides encoding the SPINK polypeptide within one or both of the ICP4 viral gene loci.
  • Embodiment 24 the recombinant herpes virus genome of any one or embodiments 5-23, wherein the recombinant herpes simplex virus genome comprises the one or more polynucleotides encoding the SPINK polypeptide within the ICP22 viral gene locus.
  • Embodiment 25 the recombinant herpes virus genome of any one of embodiments 5-24, wherein the recombinant herpes simplex virus genome comprises the one or more polynucleotides encoding the SPINK polypeptide within the UL41 viral gene locus.
  • Embodiment 26 the recombinant herpes virus genome of any one of embodiments 1-25, wherein the recombinant herpes virus genome has reduced cytotoxicity when introduced into a target cell as compared to a corresponding wild-type herpes virus genome.
  • Embodiment 27 the recombinant herpes virus genome of embodiment 26, wherein the target cell is a human cell.
  • Embodiment 28 the recombinant herpes virus genome of embodiment 26 or embodiment 27, wherein the target cell is a cell of the epidermis and/or dermis.
  • Embodiment 29 the recombinant herpes virus genome of any one of embodiments 26-28, wherein the target cell is a keratinocyte or fibroblast.
  • Embodiment 30 a herpes virus comprising the recombinant herpes virus genome of any one of embodiments 1-29.
  • Embodiment 31 the herpes virus of embodiment 30, wherein the herpes virus is replication competent.
  • Embodiment 32 the herpes virus of embodiment 30, wherein the herpes virus is replication defective.
  • Embodiment 33 the herpes virus of any one of embodiments 30-32, wherein the herpes virus has reduced cytotoxicity as compared to a corresponding wild-type herpes virus.
  • Embodiment 34 the herpes virus of any one of embodiments 30-33, wherein the herpes virus is selected from a herpes simplex virus, a varicella zoster virus, a human cytomegalovirus, a herpesvirus 6A, a herpesvirus 6B, a herpesvirus 7, a Kaposi's sarcoma-associated herpesvirus, and any derivatives thereof.
  • the herpes virus is selected from a herpes simplex virus, a varicella zoster virus, a human cytomegalovirus, a herpesvirus 6A, a herpesvirus 6B, a herpesvirus 7, a Kaposi's sarcoma-associated herpesvirus, and any derivatives thereof.
  • Embodiment 35 the herpes virus of any one of embodiments 30-34, wherein the herpes virus is a herpes simplex virus.
  • Embodiment 36 the herpes virus of embodiment 34 or embodiment 35, wherein the herpes simplex virus is an HSV-1 virus, an HSV-2 virus, or any derivatives thereof.
  • Embodiment 37 a pharmaceutical composition comprising the recombinant herpes virus genome of any one of embodiments 1-29 and/or the herpes virus of any one of embodiments 30-36 and a pharmaceutically acceptable excipient.
  • Embodiment 38 the pharmaceutical composition of embodiment 37, wherein the pharmaceutical composition is suitable for topical, transdermal, subcutaneous, intradermal, oral, sublingual, buccal, rectal, vaginal, inhaled, intravenous, intraarterial, intramuscular, intracardiac, intraosseous, intraperitoneal, transmucosal, intravitreal, subretinal, intraarticular, peri-articular, local, or epicutaneous administration.
  • Embodiment 39 the pharmaceutical composition of embodiment 37 or embodiment 38, wherein the pharmaceutical composition is suitable for topical, transdermal, subcutaneous, intradermal, or transmucosal administration.
  • Embodiment 40 the pharmaceutical composition of any one of embodiments 37-39, wherein the pharmaceutical composition is suitable for topical administration.
  • Embodiment 41 the pharmaceutical composition of any one of embodiments 37-40, wherein the pharmaceutical composition comprises a hydroxypropyl methylcellulose gel.
  • Embodiment 42 the pharmaceutical composition of any one of embodiments 37-41, wherein the pharmaceutical composition comprises a phosphate buffer.
  • Embodiment 43 the pharmaceutical composition of any one of embodiments 37-42, wherein the pharmaceutical composition comprises glycerol.
  • Embodiment 44 the pharmaceutical composition of any one of embodiments 37-43, wherein the pharmaceutical composition comprises a lipid carrier.
  • Embodiment 45 the pharmaceutical composition of any one of embodiments 37-44, wherein the pharmaceutical composition comprises a nanoparticle carrier.
  • Embodiment 46 a method of enhancing, increasing, augmenting, and/or supplementing the levels of a SPINK polypeptide in one or more cells of a subject, the method comprising administering to the subject an effective amount of the herpes virus of any one of embodiments 30-36 or the pharmaceutical composition of any one of embodiments 37-45.
  • Embodiment 47 the method of embodiment 46, wherein the SPINK polypeptide is a SPINK5 polypeptide.
  • Embodiment 48 a method of enhancing, increasing, augmenting, and/or supplementing anti-inflammatory and/or anti-microbial protection of mucous epithelia in a subject in need thereof, the method comprising administering to the subject an effective amount of the herpes virus of any one of embodiments 30-36 or the pharmaceutical composition of any one of embodiments 37-45.
  • Embodiment 49 a method of repressing desquamation in a subject in need thereof, the method comprising administering to the subject an effective amount of the herpes virus of any one of embodiments 30-36 or the pharmaceutical composition of any one of embodiments 37-45.
  • Embodiment 50 a method of reducing or treating a skin barrier defect in a subject in need thereof, the method comprising administering to the subject an effective amount of the herpes virus of any one of embodiments 30-36 or the pharmaceutical composition of any one of embodiments 37-45.
  • Embodiment 51 the method of embodiment 50, wherein the skin barrier defect is transepithelial water loss (TEWL).
  • TEWL transepithelial water loss
  • Embodiment 52 a method of providing prophylactic, palliative, or therapeutic relief of one or more signs or symptoms of Netherton Syndrome (NS) in a subject in need thereof, the method comprising administering to the subject an effective amount of the herpes virus of any one of embodiments 30-36 or the pharmaceutical composition of any one of embodiments 37-45.
  • NS Netherton Syndrome
  • Embodiment 53 the method of embodiment 52, wherein the one or more signs or symptoms of NS are selected from the group consisting of defective keratinization, a defective skin barrier, recurrent skin infections, congenital ichthyosiform erythroderma, ichthyosis linearis circumflexa, trichorrhexis invaginata, chronic skin inflammation, and any combinations thereof.
  • Embodiment 54 the method of any one of embodiments 46-53, wherein the subject is a human.
  • Embodiment 55 the method of any one of embodiments 46-54, wherein the subject's genome comprises a loss-of-function mutation in a SPINK5 gene.
  • Embodiment 56 the method of any one of embodiments 46-55, wherein the herpes virus or pharmaceutical composition is administered topically, transdermally, subcutaneously, epicutaneously, intradermally, orally, sublingually, buccally, rectally, vaginally, intravenously, intraarterially, intramuscularly, intraosseously, intracardially, intraperitoneally, transmucosally, intravitreally, subretinally, intraarticularly, periarticularly, locally, or via inhalation to the subject.
  • Embodiment 57 the method of any one of embodiments 46-56, wherein the herpes virus or pharmaceutical composition is administered topically, transdermally, subcutaneously, intradermally, or transmucosally to the subject.
  • Embodiment 58 the method of any one of embodiments 46-57, wherein the herpes virus or pharmaceutical composition is administered topically to the subject.
  • Embodiment 59 the method of any one of embodiments 46-58, wherein the skin of the subject is abraded prior to administration.
  • Example 1 Modified Herpes Simplex Virus Vectors Encoding a Human SPINK5 Protein
  • a herpes simplex virus genome ( FIG. 1A ) is first modified to inactivate one or more herpes simplex virus genes. Such modifications may decrease the toxicity of the genome in mammalian cells.
  • variants of these modified/attenuated recombinant viral constructs are generated such that they carry one or more polynucleotides encoding the desired SPINK5 polypeptide.
  • variants include: 1) a recombinant ⁇ ICP4-modified HSV-1 genome comprising expression cassettes containing the coding sequence (e.g., SEQ ID NO: 2) of a human SPINK5 polypeptide (e.g., SEQ ID NO: 7) under the control of a heterologous promoter integrated at each ICP4 locus ( FIG. 1B ); 2) a recombinant ⁇ ICP4/ ⁇ ICP22-modified HSV-1 genome comprising expression cassettes containing the coding sequence (e.g., SEQ ID NO: 2) of a human SPINK5 polypeptide (e.g., SEQ ID NO: 4) under the control of a heterologous promoter integrated at each ICP4 locus ( FIG.
  • ⁇ ICP4/ ⁇ ICP22-modified HSV-1 genome comprising an expression cassette containing the coding sequence (e.g., SEQ ID NO: 2) of a human SPINK5 polypeptide (e.g., SEQ ID NO: 4) under the control of a heterologous promoter integrated at the ICP22 locus ( FIG.
  • ⁇ ICP4/ ⁇ UL41-modified HSV-1 genome comprising an expression cassette containing the coding sequence (e.g., SEQ ID NO: 2) of a human SPINK5 polypeptide (e.g., SEQ ID NO: 4) under the control of a heterologous promoter integrated at each ICP4 locus ( FIG.
  • a recombinant ⁇ ICP4/ ⁇ UL41-modified HSV-1 genome comprising an expression cassette containing the coding sequence (e.g., SEQ ID NO: 2) of a human SPINK5 polypeptide (e.g., SEQ ID NO: 4) under the control of a heterologous promoter integrated at the UL41 locus ( FIG.
  • ⁇ ICP4/ ⁇ ICP22/ ⁇ UL41-modified HSV-1 genome comprising an expression cassette containing the coding sequence (e.g., SEQ ID NO: 2) of a human SPINK5 polypeptide (e.g., SEQ ID NO: 4) under the control of a heterologous promoter integrated at each ICP4 locus ( FIG.
  • ⁇ ICP4/ ⁇ ICP22/ ⁇ UL41-modified HSV-1 genome comprising an expression cassette containing the coding sequence (e.g., SEQ ID NO: 2) of a human SPINK5 polypeptide (e.g., SEQ ID NO: 4) under the control of a heterologous promoter integrated at the UL41 locus ( FIG.
  • ⁇ ICP4/ ⁇ ICP22/ ⁇ UL41-modified HSV-1 genome comprising an expression cassette containing the coding sequence (e.g., SEQ ID NO: 2) of a human SPINK5 polypeptide (e.g., SEQ ID NO: 4) under the control of a heterologous promoter integrated at the ICP22 locus ( FIG. 1I ).
  • modified herpes simplex virus genome vectors are transfected into engineered Vero cells that are modified to express one or more herpes virus genes. These engineered Vero cells subsequently secrete into the supernatant of the cell culture a replication-defective herpes simplex virus with the modified genomes packaged therein. The supernatant is then collected, concentrated, and sterile filtered through a 5 ⁇ m filter.
  • HSV-1 herpes simplex virus type 1
  • the “HSV-S5” vector was generated as follows: a recombinant HSV-1 was engineered to incorporate a codon-optimized human SPINK5 expression cassette containing a heterologous promoter and polyA sequence into each of the ICP4 loci. Multiple plaques of the engineered virus putatively containing the human SPINK5 cassette were picked and screened by infection in Vero cells to test for SPINK5 expression (data not shown). The highest SPINK5 producing virus, termed “HSV-S5”, was isolated and purified.
  • Viral aliquots were removed from the ⁇ 80° C. freezer and were left to defrost under the tissue culture laminar flow hood. Multiplicity of infection was calculated from the virus titer and target cell number, the appropriate volume of virus stock was diluted in cell culture medium to a final volume of 100 ⁇ L, and the prepared virus was incubated with the target cells for 1 hour at 37° C. After the hour-long infection, 2 mL of the appropriate cell culture medium was added to well of the 6-well plate, or in the case of 8 chamber slides, 4004, of medium was added.
  • Immortalized keratinocytes were plated in 6-well plates at 7 ⁇ 10 5 cells/well to achieve 90-100% confluence the following day. 48 hours after mock infection or infection with HSV-S5, cells were resuspended in 3504, RLT buffer containing DTT and homogenized by passing through a QiaShredder column according to the manufacturer's protocol. DNA and RNA were isolated using an AllPrep DNA/RNA Mini kit (Qiagen) according to the manufacturer's protocol. For qPCR/qRT-PCR analysis, 50 ng of DNA or RNA were used per reaction in a total reaction volume of 25 ⁇ L.
  • DNA quantification was determined by qPCR analysis using a Taqman® Fast Advanced Master Mix (Applied Biosystems); RNA quantification was determined by qRT-PCR analysis using Quantabio 1-Step RT-qPCR ToughMix. All samples were run in duplicate.
  • Immortalized keratinocytes were plated in 6-well plates at 7 ⁇ 10 5 cells/well to achieve 90-100% confluence the following day. 48 hours after mock infection or infection with HSV-S5, media was aspirated, cells were recovered with gentle scraping, and cell pellets were generated by centrifugation. Cells were lysed with RIPA buffer and incubated with intermittent agitation. Next, benzonase (10U) was added to each lysate for 10 minutes at room temperature. Lysates were then mixed with 4 ⁇ LDS sample buffer (Invitrogen) containing 5% 2-mercaptoethanol. Prior to loading, samples were first boiled for 10 minutes at 95° C., allowed to cool to room temperature, and then briefly centrifuged.
  • 4 ⁇ LDS sample buffer Invitrogen
  • Lysates were then run on a 4-20% Tris-Glycine gel and then transferred onto PVDF.
  • Primary antibodies (rabbit anti-human SPINK5, R&D Systems cat. no. AF8515; rabbit anti-human GAPDH, Abcam cat. no. ab9485) were incubated with the blocked blots. Blots were then incubated with secondary antibody (goat anti-rabbit IgG-AP conjugated, Sigma) for 1 hour at room temperature, the blots were washed three times with TBS for five minutes each, and the washed blots were then incubated with AP Chromogenic substrate (Invitrogen) to allow for development of the bands.
  • AP Chromogenic substrate Invitrogen
  • Immortalized keratinocytes were plated in 8-chamber slides at 1.3 ⁇ 10 5 cells/well to achieve 90-100% confluence the following day. 48 hours after mock infection or infection with HSV-S5, cells were fixed with 2% paraformaldehyde, and were permeabilized with 0.2% TritonTM X-100 for five minutes. The cells were incubated with Powerblock (BioGenex) for 30 minutes, then were incubated with rabbit anti-human SPINK5 primary antibody (Novus Biologicals cat. no. NBP1-90509) overnight. Slides were subsequently incubated with Alexa Fluor® 488-conjugated secondary antibody, and mounted with ProLong Gold antifade reagent containing DAPI.
  • Powerblock BioGenex
  • HSV-S5-infected immortalized keratinocyte cell supernatants The inhibition of recombinant human Kallikrein 5 (R&D Systems) protease activity by HSV-S5-infected immortalized keratinocyte cell supernatants was evaluated using a modified method supplied by R&D Systems. Briefly, rhKLK5 (2 ng/ ⁇ L) was preincubated with culture supernatants from HSV-S5-infected (or mock infected) cells for 5 minutes at room temperature. Following preincubation, the fluorogenic peptide Boc-VPR-AMC was added to a final concentration of 20 ⁇ M.
  • the cleavage of substrate was measured at Excitation 380 nm/Emission 460 nm using a Synergy H1 Hybrid Multi-Mode Reader every 70 seconds for 15 minutes.
  • HaCaTs Immortalized normal human keratinocytes
  • MOIs multiplicities of infection
  • SPINK5 expression was evaluated by quantitative polymerase chain reaction (qPCR), quantitative reverse transcription PCR (qRT-PCR), western blot analysis, and an enzyme-linked immunosorbent assay (ELISA) 48 hours post-infection.
  • SPINK5 was detected in infected normal keratinocytes at an MOI as low as 0.3, and appeared to show a dose-dependent increase at both the DNA ( FIG. 2A ) and transcript ( FIG. 2B ) levels up to an MOI of 3.0.
  • a concomitant dose-dependent increase in SPINK5 protein expression was observed in the cytoplasm of infected normal keratinocytes, as assessed by western blot ( FIG. 2C ).
  • HSV-S5-expressed human SPINK5 secreted from infected keratinocytes was confirmed using an enzymatic inhibition assay that measured SPINK5's ability to inhibit a native target of the SPINK5, the human serine protease Kallikrein 5 (KLK5).
  • KLK5 human serine protease Kallikrein 5
  • recombinant human KLK5 was preincubated with cell culture supernatants collected from HSV-S5-infected HaCaTs (supernatant from mock-infected cells was used as a control).
  • a synthetic, non-natural peptide substrate of human KLK5 (Boc-VPR-AMC) was added to the samples, and KLK5-mediated cleavage of the substrate was assessed in each sample.
  • the proteolytic activity of KLK5 (and its inhibition by SPINK5) could be directly quantitated by determining fluorescence resulting from the liberation of the previously quenched fluorescent AMC moiety of Boc-VPR-AMC after hydrolysis of the Arg-AMC amide bond by KLK5.
  • HSV-S5 was capable of rescuing/supplementing SPINK5 expression in human cells, the vector did not induce any major toxicity in any of the studies.
  • the data presented herein indicates that HSV-S5 is capable of inducing secretion of functional SPINK5 at therapeutically relevant levels.
  • mice were shaved, and hair follicles were removed with a hair removal product before further manipulations.
  • Tape stripping (using TegadermTM) was carried out as described previously (Ekanayake-Mudiyanselage et al. J Invest Dermatol (1998), 111(3):517-23). After tape stripping, two sites on the backs of each mouse were treated topically with the appropriate test article. To contain the topical formulation at the treatment site, sterile plastic wells covered by a transparent adhesive dressing were adhered to the skin of the animals using surgical glue. HSV-S5 (or vehicle control) formulated in a methylcellulose gel carrier was then applied to the treatment sites via injection through the transparent adhesive dressing.
  • mice were shaved before further manipulations. HSV-S5 (or vehicle control) was then injected intradermally to two sites in the backs of each mouse.
  • the animals were euthanized by CO 2 inhalation followed by cervical dislocation, and the treatment sites were removed using an 8 mm punch biopsy.
  • One half of each biopsy was quick-frozen in liquid nitrogen for qPCR/qRT-PCR analysis, while the other half was processed for immunofluorescence analysis and H&E staining.
  • Absolute quantification of SPINK5 DNA and RNA copies was performed by TaqMan Real Time PCR analysis using custom, transgene-specific primer/probe pairs.
  • Taqman® Fast Advanced Master Mix (Applied Biosystems) was used for DNA quantification (qPCR) and Quantabio 1-Step RT-qPCR ToughMix was used for RNA quantification (qRT-PCR). All samples were run in duplicate, and copy number was determined using a standard curve derived from a dilution series of plasmid standard containing a known copy number of the SPINK5 transgene.
  • the stained and rinsed sections were gradually dehydrated with ethanol (EtOH) by first rinsing twice with 95% EtOH for 2 minutes each, then twice with 100% EtOH for 2 minutes each. Sections were then cleared through three rinses with Histo-Clear for 2 minutes each, mounted with mounting media (PermountTM Mounting Medium), and covered with a coverslip. The sections were imaged approximately 24 hours after dehydration using a brightfield microscope
  • a single dose pharmacology study was conducted in immunocompetent BALB/c mice to determine feasibility of administering human SPINK5 via topical and/or intradermal administration of HSV-S5.
  • a total of 4 BALB/c mice were used for this study.
  • Prior to test article administration the backs of the mice were shaved, and hair follicles were removed using a chemical hair removal product.
  • the exposed skin was tape stripped nine times to disrupt/remove the stratum corneum and 1 ⁇ 10 8 plaque forming units (PFUs) of HSV-S5 (or vehicle control) formulated in a gel carrier were topically administered to two regions of the tape stripped skin on each mouse.
  • PFUs plaque forming units
  • 1 ⁇ 10 8 PFUs of HSV-S5 (or vehicle control) were injected at two parallel sites on the back of each animal. Table 2 below provides a synopsis of the experimental design.
  • a full thickness 8 mm biopsy was taken from each treatment site and split in half.
  • One half of each section was flash frozen in liquid nitrogen and subsequently processed for qPCR and qRT-PCR analysis in order to quantify SPINK5 DNA copy numbers and transcript levels, respectively.
  • the remaining half of each biopsy was embedded in OCT for immunofluorescence (IF).
  • FIG. 5A qPCR analysis of the topically treated, tape-stripped skin indicated that the engineered HSV genomes encoding the human SPINK5 transgene efficiently transduced disrupted skin of immunocompetent animals.
  • FIG. 5B Similar results were found after intradermal injection of HSV-S5 into fully intact skin at both the DNA ( FIG. 5C ) and RNA ( FIG. 5D ) levels. No SPINK5 DNA or RNA was detected in the vehicle treated tissues, indicating specificity of the assay for the HSV-S5 test article.
  • HSV-S5 successfully expresses human SPINK5 in vivo when administered topically and intradermally to immunocompetent mice, and (2) the recombinant SPINK5 is expressed in, and localizes to, the appropriate region of the epidermis.
  • no inflammatory infiltration or gross structural changes to the skin were observed at the HSV-S5-treated sites, confirming that HSV-S5 is well tolerated.
  • these data paired with the results of the in vitro testing, provide strong support for the safe and effective use of topical or intradermal HSV-S5 for the transient and repeated delivery of human SPINK5.
  • HSV-S5 has the potential to be a clinically beneficial, non-invasive gene therapy candidate for the treatment of Netherton Syndrome.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US16/581,150 2018-09-24 2019-09-24 Compositions and methods for the treatment of netherton syndrome Abandoned US20200093874A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/581,150 US20200093874A1 (en) 2018-09-24 2019-09-24 Compositions and methods for the treatment of netherton syndrome
US17/871,805 US11642384B2 (en) 2018-09-24 2022-07-22 Compositions and methods for the treatment of Netherton Syndrome
US18/187,884 US20230218691A1 (en) 2018-09-24 2023-03-22 Compositions and methods for treatment of netherton syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862735582P 2018-09-24 2018-09-24
US16/581,150 US20200093874A1 (en) 2018-09-24 2019-09-24 Compositions and methods for the treatment of netherton syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/871,805 Continuation US11642384B2 (en) 2018-09-24 2022-07-22 Compositions and methods for the treatment of Netherton Syndrome

Publications (1)

Publication Number Publication Date
US20200093874A1 true US20200093874A1 (en) 2020-03-26

Family

ID=68344983

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/581,150 Abandoned US20200093874A1 (en) 2018-09-24 2019-09-24 Compositions and methods for the treatment of netherton syndrome
US17/871,805 Active US11642384B2 (en) 2018-09-24 2022-07-22 Compositions and methods for the treatment of Netherton Syndrome
US18/187,884 Pending US20230218691A1 (en) 2018-09-24 2023-03-22 Compositions and methods for treatment of netherton syndrome

Family Applications After (2)

Application Number Title Priority Date Filing Date
US17/871,805 Active US11642384B2 (en) 2018-09-24 2022-07-22 Compositions and methods for the treatment of Netherton Syndrome
US18/187,884 Pending US20230218691A1 (en) 2018-09-24 2023-03-22 Compositions and methods for treatment of netherton syndrome

Country Status (6)

Country Link
US (3) US20200093874A1 (fr)
EP (1) EP3856761A1 (fr)
JP (2) JP7562515B2 (fr)
AU (2) AU2019346549B2 (fr)
CA (1) CA3112627A1 (fr)
WO (1) WO2020068862A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10829529B2 (en) 2019-02-08 2020-11-10 Krystal Biotech, Inc. Compositions and methods for delivering CFTR polypeptides
WO2022212896A1 (fr) 2021-04-02 2022-10-06 Krystal Biotech, Inc. Vecteurs viraux pour la thérapie du cancer
US11642384B2 (en) 2018-09-24 2023-05-09 Krystal Biotech, Inc. Compositions and methods for the treatment of Netherton Syndrome
WO2024214081A1 (fr) * 2023-04-13 2024-10-17 Krystal Biotech, Inc. Procédés et compositions pour le traitement des affections de l'oeil
US12128122B2 (en) 2018-04-27 2024-10-29 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011243A2 (fr) * 1996-09-11 1998-03-19 The General Hospital Corporation Virus a adn non mammalien qui possede une proteine de coque modifiee
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US20030093040A1 (en) * 2001-10-29 2003-05-15 Mikszta John A. Method and device for the delivery of a substance
US20030190637A1 (en) * 2000-03-02 2003-10-09 Alain Hovnanian Mutations in spink5 responsible for netherton's syndrome and atopic diseases
US20140341881A1 (en) * 2008-01-21 2014-11-20 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases
US20170290866A1 (en) * 2016-04-08 2017-10-12 Krystal Biotech, LLC Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
US20190040116A1 (en) * 2017-06-16 2019-02-07 Azitra Inc Compositions and methods for treatment of netherton syndrome with lekti expressing recombinant microbes

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
KR100201352B1 (ko) 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
WO1998044938A1 (fr) 1997-04-10 1998-10-15 University Of Southern California Proteines modifiees se fixant a des composants de matrice extracellulaires
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9715085D0 (en) 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
AU4680699A (en) 1998-06-12 1999-12-30 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
WO2000040734A1 (fr) 1998-12-31 2000-07-13 Arch Development Corporation Virus de l'herpes simplex recombinant utile dans le traitement des maladies neoplasiques
US6939851B1 (en) 1999-06-22 2005-09-06 Pharis Biotec Gmbh Serine proteinase inhibitors
US6835184B1 (en) 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
AU1788502A (en) 2000-11-28 2002-06-11 Univ Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
US7081483B2 (en) 2001-07-03 2006-07-25 The University Of Chicago Polyfunctional dispersants for controlling viscosity of phyllosilicates
US20030223962A1 (en) 2002-06-03 2003-12-04 Cornell Research Foundation, Inc. Delivery of gene products to the lung parenchyma via gene transfer to the pleura
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
EP1583473A2 (fr) 2003-01-16 2005-10-12 St. Johns University New York Stabilisation a base de nanoparticules de colorants fluorescents infrarouges
WO2006052285A2 (fr) 2004-05-13 2006-05-18 The Trustees Of Columbia University In The City Of New York Nanoparticules et nanogels polymeres pour l'extraction et la liberation de composes
AU2005302408B2 (en) 2004-10-28 2012-08-09 The Government of the United States of America as represented by the Department of Veterans Affairs Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
ATE382337T1 (de) 2005-04-28 2008-01-15 Nipro Corp Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
CA2605551A1 (fr) 2005-05-10 2006-11-16 Naomi Balaban Compositions pour administrer des peptides inhibant l'arniii
EP1885186B1 (fr) 2005-06-01 2015-09-02 California Institute Of Technology Procede permettant le transfert cible de genes au moyen de vecteurs viraux
US8703703B2 (en) 2006-12-20 2014-04-22 University Of Central Flordia Research Foundation, Inc. MCPIP as wound therapy
WO2008106646A2 (fr) 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Procédés et formulations pour une thérapie génique topique
BR112012025331B1 (pt) * 2010-04-06 2022-04-19 Fertility Lab Sciences, Llc Método para prever a competência de desenvolvimento e a viabilidade de um embrião candidato e kit de ensaio para aumentar a taxa de sucesso de gravidez
CN102212559B (zh) 2011-04-14 2014-04-09 郑州威瑞生物技术有限公司 一种重组的hsv扩增子载体及其用途
ES2670495T3 (es) 2011-10-11 2018-05-30 Inserm - Institut National De La Santé Et De La Recherche Médicale Tratamiento de salto de exones para epidermólisis ampollosa distrófica
GB201202561D0 (en) 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
JP2015520754A (ja) 2012-05-18 2015-07-23 オタゴ イノベーション リミテッド 創傷治癒のための組合せ治療および組成物
WO2014134412A1 (fr) 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Correction de gène à base de talen
RS57739B1 (sr) 2013-03-14 2018-12-31 Translate Bio Inc Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima
JP6726824B2 (ja) 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞
EP3099801B1 (fr) 2014-01-31 2020-03-18 Factor Bioscience Inc. Rna synthétique pour l'utilisation dans le traitement de l'épidermolyse bulleuse dystrophique
WO2015114144A1 (fr) * 2014-02-03 2015-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques de traitement du syndrôme de netherton
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
WO2017165806A1 (fr) 2016-03-25 2017-09-28 Periphagen, Inc. Vecteurs du vhs pour l'administration de nt3, et traitement de la cipn
WO2017165813A1 (fr) 2016-03-25 2017-09-28 Periphagen, Inc. Vecteurs de vhs à transduction élevée
EP3624820A1 (fr) 2017-04-21 2020-03-25 H. Hoffnabb-La Roche Ag Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
AU2019346549B2 (en) 2018-09-24 2024-09-12 Krystal Biotech, Inc. Compositions and methods for the treatment of Netherton Syndrome

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
WO1998011243A2 (fr) * 1996-09-11 1998-03-19 The General Hospital Corporation Virus a adn non mammalien qui possede une proteine de coque modifiee
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US20030190637A1 (en) * 2000-03-02 2003-10-09 Alain Hovnanian Mutations in spink5 responsible for netherton's syndrome and atopic diseases
US20030093040A1 (en) * 2001-10-29 2003-05-15 Mikszta John A. Method and device for the delivery of a substance
US20140341881A1 (en) * 2008-01-21 2014-11-20 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases
US20170290866A1 (en) * 2016-04-08 2017-10-12 Krystal Biotech, LLC Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
US20190040116A1 (en) * 2017-06-16 2019-02-07 Azitra Inc Compositions and methods for treatment of netherton syndrome with lekti expressing recombinant microbes

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128122B2 (en) 2018-04-27 2024-10-29 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic
US11642384B2 (en) 2018-09-24 2023-05-09 Krystal Biotech, Inc. Compositions and methods for the treatment of Netherton Syndrome
US10829529B2 (en) 2019-02-08 2020-11-10 Krystal Biotech, Inc. Compositions and methods for delivering CFTR polypeptides
US12522636B2 (en) 2019-02-08 2026-01-13 Krystal Biotech, Inc. Compositions and methods for delivering CFTR polypeptides
WO2022212896A1 (fr) 2021-04-02 2022-10-06 Krystal Biotech, Inc. Vecteurs viraux pour la thérapie du cancer
US11779660B2 (en) 2021-04-02 2023-10-10 Krystal Biotech, Inc. Viral vectors for cancer therapy
US11918660B2 (en) 2021-04-02 2024-03-05 Krystal Biotech, Inc. Viral vectors for cancer therapy
US12364775B2 (en) 2021-04-02 2025-07-22 Krystal Biotech, Inc. Viral vectors for cancer therapy
WO2024214081A1 (fr) * 2023-04-13 2024-10-17 Krystal Biotech, Inc. Procédés et compositions pour le traitement des affections de l'oeil

Also Published As

Publication number Publication date
CA3112627A1 (fr) 2020-04-02
AU2019346549A1 (en) 2021-04-15
JP7562515B2 (ja) 2024-10-07
EP3856761A1 (fr) 2021-08-04
US11642384B2 (en) 2023-05-09
JP2022502026A (ja) 2022-01-11
JP2025004042A (ja) 2025-01-14
AU2019346549A9 (en) 2021-04-22
AU2019346549B2 (en) 2024-09-12
US20230218691A1 (en) 2023-07-13
US20220409685A1 (en) 2022-12-29
WO2020068862A1 (fr) 2020-04-02
AU2024220106A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
US11642384B2 (en) Compositions and methods for the treatment of Netherton Syndrome
US11717547B2 (en) Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
JP2021521894A (ja) 審美的用途のための美容用タンパク質をコードする組換え核酸
US20250277237A1 (en) Compositions and Methods for the Treatment of Congenital Ichthyoses
AU2019346461B2 (en) Compositions and methods for the treatment of skin diseases
US20210317174A1 (en) Compositions and methods for delivering cftr polypeptides
AU2026202860A1 (en) Compositions and methods for the treatment of skin diseases
US20260125705A1 (en) Compositions and Methods for the Treatment of ATPase Disorders or Diseases of the Skin
WO2026094007A1 (fr) Compositions et procédés destinés au traitement de troubles de l'atpase et de maladies de la peau

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

AS Assignment

Owner name: KRYSTAL BIOTECH, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AGARWAL, POOJA;KRISHNAN, SUMA;FREEDMAN, JOHN C.;SIGNING DATES FROM 20200604 TO 20200605;REEL/FRAME:052939/0786

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION